CA3161491C - Vaporizable psychoactive alkaloid composition and preparation thereof - Google Patents
Vaporizable psychoactive alkaloid composition and preparation thereof Download PDFInfo
- Publication number
- CA3161491C CA3161491C CA3161491A CA3161491A CA3161491C CA 3161491 C CA3161491 C CA 3161491C CA 3161491 A CA3161491 A CA 3161491A CA 3161491 A CA3161491 A CA 3161491A CA 3161491 C CA3161491 C CA 3161491C
- Authority
- CA
- Canada
- Prior art keywords
- psychoactive
- alcohol
- alkaloid
- composition
- psychoactive alkaloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229930013930 alkaloid Natural products 0.000 title claims abstract description 449
- 150000003797 alkaloid derivatives Chemical class 0.000 title claims abstract description 378
- 239000000203 mixture Substances 0.000 title claims abstract description 170
- 238000002360 preparation method Methods 0.000 title description 5
- 239000000284 extract Substances 0.000 claims abstract description 150
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 95
- 238000000034 method Methods 0.000 claims abstract description 52
- 239000007788 liquid Substances 0.000 claims abstract description 44
- 230000008569 process Effects 0.000 claims abstract description 44
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 41
- 239000000194 fatty acid Substances 0.000 claims abstract description 41
- 229930195729 fatty acid Natural products 0.000 claims abstract description 41
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 31
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 28
- 150000002191 fatty alcohols Chemical class 0.000 claims abstract description 27
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 22
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 21
- 229920005862 polyol Polymers 0.000 claims abstract description 19
- 150000003077 polyols Chemical class 0.000 claims abstract description 19
- 239000000796 flavoring agent Substances 0.000 claims abstract description 12
- 235000019634 flavors Nutrition 0.000 claims abstract description 10
- 239000002904 solvent Substances 0.000 claims description 94
- 239000002002 slurry Substances 0.000 claims description 38
- 239000000706 filtrate Substances 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 229910001868 water Inorganic materials 0.000 claims description 27
- 238000001704 evaporation Methods 0.000 claims description 25
- SPCIYGNTAMCTRO-UHFFFAOYSA-N Psilocine Natural products C1=CC(O)=C2C(CCN(C)C)=CNC2=C1 SPCIYGNTAMCTRO-UHFFFAOYSA-N 0.000 claims description 23
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 23
- ZBWSBXGHYDWMAK-UHFFFAOYSA-N psilocin Chemical compound C1=CC=C(O)[C]2C(CCN(C)C)=CN=C21 ZBWSBXGHYDWMAK-UHFFFAOYSA-N 0.000 claims description 23
- 235000006708 antioxidants Nutrition 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 19
- 230000008020 evaporation Effects 0.000 claims description 18
- 239000003623 enhancer Substances 0.000 claims description 15
- -1 hendecanol) Chemical compound 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- GOQYKNQRPGWPLP-UHFFFAOYSA-N heptadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 12
- REIUXOLGHVXAEO-UHFFFAOYSA-N pentadecan-1-ol Chemical compound CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 claims description 12
- REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 11
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 claims description 10
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 10
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 10
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 claims description 10
- 235000010323 ascorbic acid Nutrition 0.000 claims description 9
- 239000011668 ascorbic acid Substances 0.000 claims description 9
- 229960005070 ascorbic acid Drugs 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 9
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims description 8
- WTPBXXCVZZZXKR-UHFFFAOYSA-N baeocystin Chemical compound C1=CC(OP(O)(O)=O)=C2C(CCNC)=CNC2=C1 WTPBXXCVZZZXKR-UHFFFAOYSA-N 0.000 claims description 8
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 8
- FIPPFBHCBUDBRR-UHFFFAOYSA-N henicosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCO FIPPFBHCBUDBRR-UHFFFAOYSA-N 0.000 claims description 8
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 claims description 8
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 8
- XGFDHKJUZCCPKQ-UHFFFAOYSA-N nonadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCO XGFDHKJUZCCPKQ-UHFFFAOYSA-N 0.000 claims description 8
- IKQGYCWFBVEAKF-UHFFFAOYSA-N norbaeocystin Chemical compound C1=CC(OP(O)(O)=O)=C2C(CCN)=CNC2=C1 IKQGYCWFBVEAKF-UHFFFAOYSA-N 0.000 claims description 8
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 claims description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 8
- TYWMIZZBOVGFOV-UHFFFAOYSA-N tetracosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCO TYWMIZZBOVGFOV-UHFFFAOYSA-N 0.000 claims description 8
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229960004106 citric acid Drugs 0.000 claims description 7
- 235000015165 citric acid Nutrition 0.000 claims description 7
- 229920005903 polyol mixture Polymers 0.000 claims description 7
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 6
- 229960002666 1-octacosanol Drugs 0.000 claims description 6
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 claims description 6
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 claims description 6
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- 235000003599 food sweetener Nutrition 0.000 claims description 6
- 229940041616 menthol Drugs 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 6
- 239000003765 sweetening agent Substances 0.000 claims description 6
- 229960000541 cetyl alcohol Drugs 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 239000012260 resinous material Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 5
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 4
- PKBSGDQYUYBUDY-UHFFFAOYSA-N 1-nonacosanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCO PKBSGDQYUYBUDY-UHFFFAOYSA-N 0.000 claims description 4
- FKIRTWDHOWAQGX-UHFFFAOYSA-N 4-hydroxytryptamine Chemical compound C1=CC(O)=C2C(CCN)=CNC2=C1 FKIRTWDHOWAQGX-UHFFFAOYSA-N 0.000 claims description 4
- 229920002101 Chitin Polymers 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- QOEHNLSDMADWEF-UHFFFAOYSA-N I-Dotriacontanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO QOEHNLSDMADWEF-UHFFFAOYSA-N 0.000 claims description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 4
- VTTONGPRPXSUTJ-UHFFFAOYSA-N bufotenin Chemical compound C1=C(O)C=C2C(CCN(C)C)=CNC2=C1 VTTONGPRPXSUTJ-UHFFFAOYSA-N 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 229960000735 docosanol Drugs 0.000 claims description 4
- 239000003925 fat Substances 0.000 claims description 4
- 235000019197 fats Nutrition 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- ULCZGKYHRYJXAU-UHFFFAOYSA-N heptacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCO ULCZGKYHRYJXAU-UHFFFAOYSA-N 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- 239000001993 wax Substances 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- MTJOWJUQGYWRHT-UHFFFAOYSA-N 3-[2-(methylamino)ethyl]-1h-indol-4-ol Chemical compound C1=CC(O)=C2C(CCNC)=CNC2=C1 MTJOWJUQGYWRHT-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- OIIPFLWAQQNCHA-UHFFFAOYSA-N aeruginascin Chemical compound C1=CC(OP(O)([O-])=O)=C2C(CC[N+](C)(C)C)=CNC2=C1 OIIPFLWAQQNCHA-UHFFFAOYSA-N 0.000 claims description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 229960004488 linolenic acid Drugs 0.000 claims description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- CFOQKXQWGLAKSK-KTKRTIGZSA-N (13Z)-docosen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCO CFOQKXQWGLAKSK-KTKRTIGZSA-N 0.000 claims description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 2
- JXNPEDYJTDQORS-HZJYTTRNSA-N (9Z,12Z)-octadecadien-1-ol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCO JXNPEDYJTDQORS-HZJYTTRNSA-N 0.000 claims description 2
- IKYKEVDKGZYRMQ-PDBXOOCHSA-N (9Z,12Z,15Z)-octadecatrien-1-ol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCO IKYKEVDKGZYRMQ-PDBXOOCHSA-N 0.000 claims description 2
- JXNPEDYJTDQORS-AVQMFFATSA-N (9e,12e)-octadeca-9,12-dien-1-ol Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCO JXNPEDYJTDQORS-AVQMFFATSA-N 0.000 claims description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 2
- 239000005968 1-Decanol Substances 0.000 claims description 2
- XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical compound CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 claims description 2
- 229940094997 1-tetracosanol Drugs 0.000 claims description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 claims description 2
- DKGXIVRSAKPDHF-UHFFFAOYSA-N 6-chloro-3-methyl-1-phenylpyrimidine-2,4-dione Chemical compound O=C1N(C)C(=O)C=C(Cl)N1C1=CC=CC=C1 DKGXIVRSAKPDHF-UHFFFAOYSA-N 0.000 claims description 2
- IKYKEVDKGZYRMQ-IUQGRGSQSA-N 9,12,15-Octadecatrien-1-ol Chemical compound CC\C=C\C\C=C\C\C=C\CCCCCCCCO IKYKEVDKGZYRMQ-IUQGRGSQSA-N 0.000 claims description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- XZAGBDSOKNXTDT-UHFFFAOYSA-N Sucrose monopalmitate Chemical compound CCCCCCCCCCCCCCCC(O)=O.OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(CO)O1 XZAGBDSOKNXTDT-UHFFFAOYSA-N 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 2
- 235000021342 arachidonic acid Nutrition 0.000 claims description 2
- 229940114079 arachidonic acid Drugs 0.000 claims description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 2
- HIYGARYIJIZXGW-UHFFFAOYSA-N bufotenidine Chemical compound C1=C([O-])C=C2C(CC[N+](C)(C)C)=CNC2=C1 HIYGARYIJIZXGW-UHFFFAOYSA-N 0.000 claims description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 2
- 229940074979 cetyl palmitate Drugs 0.000 claims description 2
- ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 2
- 229960003479 colfosceril palmitate Drugs 0.000 claims description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 2
- 229960001484 edetic acid Drugs 0.000 claims description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 235000003969 glutathione Nutrition 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 2
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 claims description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 2
- 229930013686 lignan Natural products 0.000 claims description 2
- 150000005692 lignans Chemical class 0.000 claims description 2
- 235000009408 lignans Nutrition 0.000 claims description 2
- JXNPEDYJTDQORS-UHFFFAOYSA-N linoleyl alcohol Natural products CCCCCC=CCC=CCCCCCCCCO JXNPEDYJTDQORS-UHFFFAOYSA-N 0.000 claims description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 2
- 235000019136 lipoic acid Nutrition 0.000 claims description 2
- 229940043348 myristyl alcohol Drugs 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 claims description 2
- DKBBOWMEYUBDGN-UHFFFAOYSA-N octadec-9-ene-1,12-diol Chemical compound CCCCCCC(O)CC=CCCCCCCCCO DKBBOWMEYUBDGN-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229960002969 oleic acid Drugs 0.000 claims description 2
- 235000021313 oleic acid Nutrition 0.000 claims description 2
- ALSTYHKOOCGGFT-MDZDMXLPSA-N oleyl alcohol Chemical compound CCCCCCCC\C=C\CCCCCCCCO ALSTYHKOOCGGFT-MDZDMXLPSA-N 0.000 claims description 2
- 229940055577 oleyl alcohol Drugs 0.000 claims description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 2
- 229940098695 palmitic acid Drugs 0.000 claims description 2
- LBIYNOAMNIKVKF-FPLPWBNLSA-N palmitoleyl alcohol Chemical compound CCCCCC\C=C/CCCCCCCCO LBIYNOAMNIKVKF-FPLPWBNLSA-N 0.000 claims description 2
- LBIYNOAMNIKVKF-UHFFFAOYSA-N palmitoleyl alcohol Natural products CCCCCCC=CCCCCCCCCO LBIYNOAMNIKVKF-UHFFFAOYSA-N 0.000 claims description 2
- MNBKLUUYKPBKDU-BBECNAHFSA-N palmitoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MNBKLUUYKPBKDU-BBECNAHFSA-N 0.000 claims description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000020944 retinol Nutrition 0.000 claims description 2
- 229960003471 retinol Drugs 0.000 claims description 2
- 239000011607 retinol Substances 0.000 claims description 2
- 239000011769 retinyl palmitate Substances 0.000 claims description 2
- 229940108325 retinyl palmitate Drugs 0.000 claims description 2
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 239000011669 selenium Substances 0.000 claims description 2
- 229940091258 selenium supplement Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 229960004274 stearic acid Drugs 0.000 claims description 2
- MINQXXMPECOAGH-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO MINQXXMPECOAGH-UHFFFAOYSA-N 0.000 claims description 2
- 229960002663 thioctic acid Drugs 0.000 claims description 2
- 229940035936 ubiquinone Drugs 0.000 claims description 2
- 229940057402 undecyl alcohol Drugs 0.000 claims description 2
- 229940116269 uric acid Drugs 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000008240 homogeneous mixture Substances 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 46
- 239000011347 resin Substances 0.000 description 61
- 229920005989 resin Polymers 0.000 description 61
- 239000000243 solution Substances 0.000 description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 239000002585 base Substances 0.000 description 22
- 239000002253 acid Substances 0.000 description 21
- 238000010828 elution Methods 0.000 description 19
- 239000002028 Biomass Substances 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 239000008186 active pharmaceutical agent Substances 0.000 description 16
- 239000012535 impurity Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 230000030609 dephosphorylation Effects 0.000 description 14
- 238000006209 dephosphorylation reaction Methods 0.000 description 14
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 13
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 description 13
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
- 238000001223 reverse osmosis Methods 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 239000003456 ion exchange resin Substances 0.000 description 11
- 229920003303 ion-exchange polymer Polymers 0.000 description 11
- 150000002576 ketones Chemical class 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 235000011121 sodium hydroxide Nutrition 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 235000011167 hydrochloric acid Nutrition 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 7
- 238000001179 sorption measurement Methods 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
- 229920001429 chelating resin Polymers 0.000 description 6
- 235000011007 phosphoric acid Nutrition 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 235000019832 sodium triphosphate Nutrition 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 150000001450 anions Chemical class 0.000 description 5
- 239000003729 cation exchange resin Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 238000009834 vaporization Methods 0.000 description 5
- 230000008016 vaporization Effects 0.000 description 5
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 4
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241001062357 Psilocybe cubensis Species 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- 239000001099 ammonium carbonate Substances 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 4
- 229940078495 calcium phosphate dibasic Drugs 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000001540 sodium lactate Substances 0.000 description 4
- 235000011088 sodium lactate Nutrition 0.000 description 4
- 229940005581 sodium lactate Drugs 0.000 description 4
- 230000001839 systemic circulation Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000007605 air drying Methods 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000003957 anion exchange resin Substances 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000002031 ethanolic fraction Substances 0.000 description 3
- 230000003382 ingestive effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 235000011118 potassium hydroxide Nutrition 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000006200 vaporizer Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- RWYRUDPAALLKPX-UHFFFAOYSA-N 2,2-difluoro-n-methylethanamine;hydrochloride Chemical compound Cl.CNCC(F)F RWYRUDPAALLKPX-UHFFFAOYSA-N 0.000 description 2
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 2
- RMPOMMZKJNCOTM-UHFFFAOYSA-O 4-hydroxy-N,N,N-trimethyltryptamine(1+) Chemical compound C1=CC(O)=C2C(CC[N+](C)(C)C)=CNC2=C1 RMPOMMZKJNCOTM-UHFFFAOYSA-O 0.000 description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000001749 Calcium fumarate Substances 0.000 description 2
- 241001236189 Conocybe Species 0.000 description 2
- 241001059394 Copelandia Species 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 241001562190 Galerina Species 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241001669525 Gymnopilus Species 0.000 description 2
- 241001237927 Inocybe Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241001236144 Panaeolus Species 0.000 description 2
- 241001059392 Pholiotina Species 0.000 description 2
- 241000958500 Pluteus Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000001747 Potassium fumarate Substances 0.000 description 2
- 241001237914 Psilocybe Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000001744 Sodium fumarate Substances 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- ZQKXOSJYJMDROL-UHFFFAOYSA-H aluminum;trisodium;diphosphate Chemical compound [Na+].[Na+].[Na+].[Al+3].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O ZQKXOSJYJMDROL-UHFFFAOYSA-H 0.000 description 2
- LCQXXBOSCBRNNT-UHFFFAOYSA-K ammonium aluminium sulfate Chemical compound [NH4+].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O LCQXXBOSCBRNNT-UHFFFAOYSA-K 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 235000012501 ammonium carbonate Nutrition 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 2
- 235000011092 calcium acetate Nutrition 0.000 description 2
- 239000001639 calcium acetate Substances 0.000 description 2
- 229960005147 calcium acetate Drugs 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 2
- 239000001354 calcium citrate Substances 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 235000019296 calcium fumarate Nutrition 0.000 description 2
- 239000004227 calcium gluconate Substances 0.000 description 2
- 235000013927 calcium gluconate Nutrition 0.000 description 2
- 229960004494 calcium gluconate Drugs 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 235000011116 calcium hydroxide Nutrition 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 2
- 239000000292 calcium oxide Substances 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- 235000012255 calcium oxide Nutrition 0.000 description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019820 disodium diphosphate Nutrition 0.000 description 2
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- GYQBBRRVRKFJRG-UHFFFAOYSA-L disodium pyrophosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GYQBBRRVRKFJRG-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- RERZNCLIYCABFS-UHFFFAOYSA-N harmaline Chemical compound C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 description 2
- 229940005740 hexametaphosphate Drugs 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000016337 monopotassium tartrate Nutrition 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 229960004838 phosphoric acid Drugs 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- SHPKCSFVQGSAJU-SEPHDYHBSA-L potassium fumarate Chemical compound [K+].[K+].[O-]C(=O)\C=C\C([O-])=O SHPKCSFVQGSAJU-SEPHDYHBSA-L 0.000 description 2
- 235000019295 potassium fumarate Nutrition 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- PHZLMBHDXVLRIX-UHFFFAOYSA-M potassium lactate Chemical compound [K+].CC(O)C([O-])=O PHZLMBHDXVLRIX-UHFFFAOYSA-M 0.000 description 2
- 235000011085 potassium lactate Nutrition 0.000 description 2
- 239000001521 potassium lactate Substances 0.000 description 2
- 229960001304 potassium lactate Drugs 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- GJPYYNMJTJNYTO-UHFFFAOYSA-J sodium aluminium sulfate Chemical compound [Na+].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GJPYYNMJTJNYTO-UHFFFAOYSA-J 0.000 description 2
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229960001790 sodium citrate Drugs 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 235000019294 sodium fumarate Nutrition 0.000 description 2
- 229940005573 sodium fumarate Drugs 0.000 description 2
- 235000012207 sodium gluconate Nutrition 0.000 description 2
- 239000000176 sodium gluconate Substances 0.000 description 2
- 229940005574 sodium gluconate Drugs 0.000 description 2
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 2
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 2
- 229940083608 sodium hydroxide Drugs 0.000 description 2
- 239000001476 sodium potassium tartrate Substances 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000013337 tricalcium citrate Nutrition 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 2
- 235000019801 trisodium phosphate Nutrition 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000000718 cholinopositive effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003571 electronic cigarette Substances 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 230000002743 euphoric effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000003400 hallucinatory effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000011346 highly viscous material Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 1
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 1
- 229940075559 piperine Drugs 0.000 description 1
- 235000019100 piperine Nutrition 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001337 psychedelic effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
This liquid composition includes a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The vaporizble psychoactive alkaloid composition includes an alcohol or polyol carrier, fatty acid, fatty alcohol, optional antioxidant, optional flavorant, and optional further excipients. A process for obtaining a vaporizble psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid, and standardizing it to a specific concentration by adding measured quantities of excipients.
Description
Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
VAPORIZABLE PSYCHOACTIVE ALKALOID COMPOSITION
AND PREPARATION THEREOF
TECHNICAL FIELD
[0001] This application relates to a vaporizable composition. More specifically, the present invention relates to a vaporizable composition of psychoactive alkaloids for human intake. The present invention also relates to a process for preparing the vaporizable composition.
BACKGROUND
PSU005c-PCT
VAPORIZABLE PSYCHOACTIVE ALKALOID COMPOSITION
AND PREPARATION THEREOF
TECHNICAL FIELD
[0001] This application relates to a vaporizable composition. More specifically, the present invention relates to a vaporizable composition of psychoactive alkaloids for human intake. The present invention also relates to a process for preparing the vaporizable composition.
BACKGROUND
[0002] A psychoactive substance is a chemical substance that changes brain function and results in alterations in perception, mood, consciousness, cognition, or behavior.
The psychoactivity of these substances may include sedative, stimulant, euphoric, deliriant, and hallucinogenic effects. These substances have been used recreationally, to purposefully improve performance or alter one's consciousness, and as entheogens for ritual, spiritual, or shamanic purposes. Some categories of psychoactive compounds have also shown therapeutic values and are prescribed by physicians and other healthcare practitioners.
The psychoactivity of these substances may include sedative, stimulant, euphoric, deliriant, and hallucinogenic effects. These substances have been used recreationally, to purposefully improve performance or alter one's consciousness, and as entheogens for ritual, spiritual, or shamanic purposes. Some categories of psychoactive compounds have also shown therapeutic values and are prescribed by physicians and other healthcare practitioners.
[0003] The active constituents of the majority of psychoactive organisms, such as plants, fungi, animals, or yeasts, fall within a class of basic, naturally occurring, nitrogen-containing, organic compounds known as alkaloids (e.g. nicotine, morphine, cocaine, mescaline, caffeine, ephedrine, psilocin). Alkaloids have a wide range of pharmacological activities including antimalarial, antiasthma, anticancer, cholinomimetic, vasodilatory, antiarrhythmic, analgesic, antibacterial, and antihyperglycemic activities. Many alkaloids have found use in traditional or modern medicine, or as starting points for drug discovery. Recently, psychotropic and stimulant activities of psychoactive alkaloids have been gaining interest from researchers as therapeutic agents for treating various conditions such as alcoholism, opioid addiction and pain to name a few.
[0004] Psychoactive alkaloids present in natural sources can be broadly divided into two categories, which are phosphorylated psychoactive alkaloids and dephosphorylated psychoactive alkaloids, although other non-phosphorylatable psychoactive alkaloids may also be present in a natural source. Phosphorylated psychoactive alkaloids are phosphoric acid esters of dephosphorylated psychoactive alkaloids and are Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
biosynthesized in natural sources. Dephosphorylated forms of these psychoactive alkaloids are the bioactive forms that are converted from the phosphorylated form through phosphatase action or chemical hydrolysis. In the human body, upon ingestion, phosphorylated psychoactive alkaloids are dephosphorylated to their corresponding dephosphorylated bioactive forms upon the action of endogenous phosphatase enzymes, which are predominantly found in the gut. For example, to achieve its desired effect, psilocybin must be dephosphorylated to psilocin by a phosphatase enzyme in the gastrointestinal tract.
PSU005c-PCT
biosynthesized in natural sources. Dephosphorylated forms of these psychoactive alkaloids are the bioactive forms that are converted from the phosphorylated form through phosphatase action or chemical hydrolysis. In the human body, upon ingestion, phosphorylated psychoactive alkaloids are dephosphorylated to their corresponding dephosphorylated bioactive forms upon the action of endogenous phosphatase enzymes, which are predominantly found in the gut. For example, to achieve its desired effect, psilocybin must be dephosphorylated to psilocin by a phosphatase enzyme in the gastrointestinal tract.
[0005] Oral administration of phosphorylated psychoactive alkaloid compositions via the human gastrointestinal tract allows the conversion of the phosphorylated form to the corresponding biological effective dephosphorylated form. Additionally, the oral route of administration is convenient and ensures patient compliance. However, bioavailability of active pharmaceutical ingredients (APIs) via enteric administration is heavily dependent on an ingredient's ability to be absorbed across the intestinal epithelium and first pass metabolism. Enteric routes of administration also pose challenges such as long onset of action, gastric irritation, etc. Further, the ingestion of dosage forms via the oral route, which involves chewing or swallowing, is problematic for children and geriatric patients.
[0006] Often, to overcome these challenges, administration of an API is done via parenteral and topical routes. Delivery of APIs via these routes of administration allows bypassing the first pass metabolism. Furthermore, onset of action of the API
is faster than oral ingestion. Dosage forms for administration of psychoactive alkaloids via parenteral routes, such as nasal sprays, inhalers, sublingual absorption, and like have been considered by researchers.
is faster than oral ingestion. Dosage forms for administration of psychoactive alkaloids via parenteral routes, such as nasal sprays, inhalers, sublingual absorption, and like have been considered by researchers.
[0007] International application PCT/US2020/040826 to Arnold discloses parenteral methods of delivering psilocin and psilocybin, without distinguishing between the two.
[0008] However, parenteral routes of administration do not facilitate the dephosphorylation of phosphorylated psychoactive alkaloids because they are delivered to an area of the body where little to no dephosphorylation occurs. Thus, often only little to none of the corresponding bioactive dephosphorylated psychoactive alkaloids are delivered to the intended site of action.
[0009] Additionally, psychoactive alkaloid extracts are often present in form of a sticky tar, which is difficult to handle or standardize into compositions with specific amounts of psychoactive alkaloids that can be formulated into desired dosage forms.
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
[0010] This background information is provided to reveal information believed by the applicant to be of possible relevance to the present invention. No admission is necessarily intended, nor should be construed, that any of the preceding information constitutes prior art against the present invention.
SUMMARY OF INVENTION
SUMMARY OF INVENTION
[0011] The inventors have realized that there is a need for a non-ingestive psychoactive alkaloid composition capable of providing desired levels of bioactivity in the systemic circulation. In particular, there is need for a non-ingestive psychoactive alkaloid composition that allows for rapid delivery of the psychoactive alkaloid into the systemic circulation, and does not adversely affect the bioavailability of the psychoactive alkaloid, thus allowing the psychoactive alkaloid to achieve the desired psychoactive effects. The psychoactive alkaloid composition is a vaporizable composition made with a predominantly dephosphorylated psychoactive alkaloid, an alcohol or polyol carrier, a fatty acid, a fatty alcohol, an optional antioxidant, optional flavoring, and optionally one or more further excipients. Use of a dephosphorylated psychoactive alkaloid allows for a non-ingestive delivery mechanism, with its attendant benefits and without the downside of a lack of an available dephosphorylation process within the body. The psychoactive alkaloids may be extracted or synthetic, and may initially be provided in either powder or liquid form. The further excipients may include a bioavailability enhancer or a sweetener, or both.
[0012] Disclosed is a liquid, vaporizable psychoactive alkaloid composition made by mixing, by weight: 0.1-15% of a psychoactive alkaloid component; 5-71.9% of alcohol, polyol, or alcohol and polyol mixture; 2-78.1% of fatty acid; 5-40% of fatty alcohol; 0-10% of antioxidant; and 0-10% of flavorant.
[0013] Also disclosed is a process for obtaining a liquid, vaporizable psychoactive alkaloid composition, the process comprising: extracting psychoactive alkaloid from a dried powdered psychoactive alkaloid source, using an acidified solvent with a pH of 3.5 or lower, to obtain a psychoactive alkaloid liquid; adjusting the pH of the psychoactive alkaloid liquid to a pH ranging from 3.5-4.5; evaporating the acidified solvent from the psychoactive alkaloid liquid to obtain a psychoactive alkaloid extract; and mixing, by weight, 0.1-15% of the psychoactive alkaloid extract, 5-71.9% of alcohol, polyol, or alcohol and polyol mixture, 2-78.1% of fatty acid, 5-40% of fatty alcohol, 0-10% of Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
antioxidant and 0-10% of flavorant to form the liquid, vaporizable psychoactive alkaloid composition.
PSU005c-PCT
antioxidant and 0-10% of flavorant to form the liquid, vaporizable psychoactive alkaloid composition.
[0014] This summary does not necessarily describe all features of the invention in detail and is not intended to limit the invention.
BRIEF DESCRIPTION OF DRAWINGS
BRIEF DESCRIPTION OF DRAWINGS
[0015] The following drawings illustrate embodiments of the invention, which should not be construed as restricting the scope of the invention in any way.
[0016] FIG. 1 illustrates the steps of a process for obtaining a psychoactive alkaloid extract with dephosphorylation control, according to an embodiment of the present invention.
[0017] FIG. 2 illustrates the steps of a process for obtaining a purified psychoactive alkaloid extract according to an embodiment of the present invention.
[0018] FIG. 3 illustrates the key steps of a process for obtaining a vaporizable psychoactive alkaloid composition, according to an embodiment of the present invention.
[0019] FIG. 4 illustrates a schematic diagram of the apparatus used for obtaining vaporizable psychoactive alkaloid compositions according to embodiments of the present invention.
DESCRIPTION
A. Glossary
DESCRIPTION
A. Glossary
[0020] To facilitate the understanding of this invention, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present invention. Terms such as "a", "an" and "the" are not intended to refer to only a singular entity but include the general class of which a specific example may be used for illustration. Terms such as "organism", "ester", "alcohol" and "alkaloid" are used as uncountable nouns, unless the context clearly indicates that a specific type of organism, ester, alcohol or alkaloid is being referred to. The terminology herein is used to describe specific embodiments of the invention, but its usage does not delimit the invention, except as outlined in the claims.
[0021] The term "psychoactive alkaloid" used herein refers to alkaloids that upon ingestion or other bodily intake are capable of changing brain function, for example resulting in alterations in perception, mood, consciousness, cognition, or behavior. The Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
psychoactive alkaloid to which the present invention applies is predominantly a dephosphorylated psychoactive alkaloid, rather than a phosphorylated alkaloid or non-phosphorylatable alkaloid.
PSU005c-PCT
psychoactive alkaloid to which the present invention applies is predominantly a dephosphorylated psychoactive alkaloid, rather than a phosphorylated alkaloid or non-phosphorylatable alkaloid.
[0022] The term "psychoactive alkaloid source" used herein refers to an organism such as a fungus, a mycelium, a spore, a plant, a bacterium, an animal or a yeast, which has in it a phosphorylated psychoactive alkaloid, a dephosphorylated psychoactive alkaloid, or a combination or both. The source of the psychoactive alkaloid can also be an extract or a solution with a phosphorylated psychoactive alkaloid, a dephosphorylated psychoactive alkaloid, or a combination of both.
[0023] The term "phosphorylatable" refers to psychoactive alkaloids that have phosphorylated derivatives and includes psychoactive alkaloids in both their phosphorylated and dephosphorylated forms.
[0024] The term "psychoactive alkaloid composition" used herein can also be referred to as "composition" and describes a mixture of a psychoactive alkaloid possibly with extracted impurities, and one or more excipients. The composition can be of pharmaceutical, nutraceutical, or veterinarian grade.
[0025] The term "psychoactive alkaloid liquid" used herein refers to psychoactive alkaloid obtained in liquid form after a dried powdered biomass of a psychoactive alkaloid source has been extracted using an acidified solvent or a basified solvent. The liquid form can be a solution or a slurry, and may or may not be filtered.
[0026] The term "purified psychoactive alkaloid solution" refers to a solution of one or more desired psychoactive alkaloids, where the solution is free of impurities or contains fewer impurities compared to a similar psychoactive alkaloid solution that has not undergone any purification. The purified solution is obtained after a psychoactive alkaloid extracted from its source has been purified using a resinous material as described herein. Complete or partial evaporation of solvent from the purified psychoactive alkaloid solution results in a purified psychoactive alkaloid extract.
[0027] The term "psychoactive alkaloid extract" used herein refers to a psychoactive alkaloid extract obtained by an extraction process described herein or other extraction process. The extract can be in a powdered, semi-solid or slurry form.
[0028] The term "purified psychoactive alkaloid extract" used herein refers to a psychoactive alkaloid extract that has been purified using resinous material as described herein or otherwise. The purified psychoactive alkaloid extract has fewer Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
impurities compared to a similar psychoactive alkaloid extract that has not undergone any purification. The extract can be in a powdered or a semi-solid or slurry form.
PSU005c-PCT
impurities compared to a similar psychoactive alkaloid extract that has not undergone any purification. The extract can be in a powdered or a semi-solid or slurry form.
[0029] As used herein, the expression "standardization of" or "standardizing"
the psychoactive alkaloid extract refers to adding a measured amount of one or more excipients to a psychoactive alkaloid extract or synthetic psychoactive alkaloid to achieve a psychoactive alkaloid composition or a vaporizable psychoactive alkaloid composition. Addition of a pre-calculated percentage concentration of non-active pharmaceutical ingredients to the psychoactive alkaloid extract or synthetic psychoactive alkaloid results in standardization of the psychoactive alkaloid composition or vaporizable psychoactive alkaloid composition. The standardization process ensures that the psychoactive alkaloid composition or vaporizable psychoactive alkaloid composition has a specific amount of total psychoactive alkaloid content in the composition. This specific amount may be accurate up to two or three significant figures. This specific amount is defined as a percentage by weight and can be selected by a person of skill in the art according to preference.
the psychoactive alkaloid extract refers to adding a measured amount of one or more excipients to a psychoactive alkaloid extract or synthetic psychoactive alkaloid to achieve a psychoactive alkaloid composition or a vaporizable psychoactive alkaloid composition. Addition of a pre-calculated percentage concentration of non-active pharmaceutical ingredients to the psychoactive alkaloid extract or synthetic psychoactive alkaloid results in standardization of the psychoactive alkaloid composition or vaporizable psychoactive alkaloid composition. The standardization process ensures that the psychoactive alkaloid composition or vaporizable psychoactive alkaloid composition has a specific amount of total psychoactive alkaloid content in the composition. This specific amount may be accurate up to two or three significant figures. This specific amount is defined as a percentage by weight and can be selected by a person of skill in the art according to preference.
[0030] The term "resin" as used herein is intended to refer to a solid or highly viscous substance of plant, mineral, or synthetic origin that has been typically converted into a polymer. Resins are usually mixtures of organic compounds. They are typically used in chromatographic techniques as a stationary phase to purify and separate compounds depending on their polarity. Resins can be physically or chemically modified to provide specificity to bind or repel particular molecules within sometimes very complex mixtures.
[0031] As used herein, the term "ion exchange resin" refers to an insoluble organic polymer containing charged groups that attract and hold oppositely charged ions present in a surrounding solution in exchange for counterions previously held.
Suitable ion exchange resins to be used herein contain cationic groups that attract and hold anions present in a surrounding solution and are sometimes referred to as "anion ion-exchange resins". Similarly, other ion exchange resins used herein contain anionic groups that attract and hold cations present in a surrounding solution and are sometimes referred to as "cation ion-exchange resins".
Suitable ion exchange resins to be used herein contain cationic groups that attract and hold anions present in a surrounding solution and are sometimes referred to as "anion ion-exchange resins". Similarly, other ion exchange resins used herein contain anionic groups that attract and hold cations present in a surrounding solution and are sometimes referred to as "cation ion-exchange resins".
[0032] The term "macroporous resin" as used herein refers to a nonionic, cation or anion resin with very small, highly cross-linked polymer particles with tiny channels.
Macroporous resins are generally used for the adsorption of organic constituents due to their hydrophobic properties and are thus used to separate and purify compounds. The adsorption capacity of macroporous resins not only correlates with the physical and Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
chemical properties of the adsorbent, but also with the size and chemical features of the adsorbed substance.
Macroporous resins are generally used for the adsorption of organic constituents due to their hydrophobic properties and are thus used to separate and purify compounds. The adsorption capacity of macroporous resins not only correlates with the physical and Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
chemical properties of the adsorbent, but also with the size and chemical features of the adsorbed substance.
[0033] The term "adsorbed psychoactive alkaloid" refers to one or more alkaloids that are adsorbed onto a resinous material.
[0034] The term "purified water" includes deionized water, distilled water, reverse osmosis water, or otherwise purified water which is substantially without free ions.
[0035] As used herein, the term "specific amount" when referring to a total psychoactive alkaloid content means a desired percentage, accurate, for example, to one or two decimal places or one, two or three significant figures, of total psychoactive alkaloid content in a psychoactive alkaloid composition or a psychoactive alkaloid extract. The specific amount is defined as a percentage by weight and can be selected by a person of skill in the art according to preference.
[0036] The term "specific pH" herein refers to a definite pH value of a solvent or a psychoactive alkaloid liquid obtained by adding an acidified solvent or a basified solvent.
[0037] The term "desired amount" herein refers to an amount of a phosphorylated psychoactive alkaloid or a dephosphorylated psychoactive alkaloid in a total psychoactive alkaloid content, in the psychoactive alkaloid liquid, extract or composition. The amount of each of these alkaloids is controlled by the process for making the psychoactive alkaloid extract or psychoactive alkaloid composition.
The amounts can be altered by a person of skill in the art according to preference. The amounts are usually percentages by weight that may be accurate up to two or three significant figures, or they may be ranges.
The amounts can be altered by a person of skill in the art according to preference. The amounts are usually percentages by weight that may be accurate up to two or three significant figures, or they may be ranges.
[0038] The "impurities" herein are commonly undesired, but not necessarily harmful, substances encountered while extracting psychoactive alkaloids from a natural source.
Impurities may include sugars, carbohydrates, chitin, chitosan, fats, minerals, waxes, and/or proteins. The impurities being removed from a psychoactive alkaloid extract will vary depending on the source of the psychoactive alkaloid. Their removal increases the concentration of the desired psychoactive alkaloids remaining in the extract.
Impurities may include sugars, carbohydrates, chitin, chitosan, fats, minerals, waxes, and/or proteins. The impurities being removed from a psychoactive alkaloid extract will vary depending on the source of the psychoactive alkaloid. Their removal increases the concentration of the desired psychoactive alkaloids remaining in the extract.
[0039] The term "total psychoactive alkaloid content" used herein refers to the total amount of psychoactive alkaloid present in the psychoactive alkaloid composition. The amount is usually a percentage by weight that may be accurate up to two or three significant figures.
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
[0040] The term "active pharmaceutical ingredient" or "API" used herein refers to an active ingredient in a pharmaceutical composition or pharmaceutical drug that is biologically active.
[0041] The term "non-active pharmaceutical ingredients" used herein refers to non-medical ingredients of a composition which do not have any have any effect on the body. They are generally used to improve stability of a composition's formulation, bulk up formulations, and more. The term as used herein includes a polymer, a carrier, and one or more other excipients.
[0042] The term "bioavailability" used herein refers to the fraction of an API
that is available in the systemic circulation after administration. This fraction of API in the systemic circulation is therefore available for delivery to the intended site of action.
that is available in the systemic circulation after administration. This fraction of API in the systemic circulation is therefore available for delivery to the intended site of action.
[0043] The term "rapid delivery" means initial immediate rapid release and delivery of an API from a composition. The rapid delivery is typically followed by a time-dependent reduction in release of the API from the composition or device and delivery of the drug to the plasma.
[0044] The term "excipient" means any component added to an active ingredient to make a composition. An excipient is inert in relation to the active ingredient, in that it essentially does not act in the same way as the active ingredient. An excipient may be completely inert, or it may have some other property that protects the integrity of the active ingredient or assists its uptake into the human body. There are multiple types of excipient, each having a different purpose, and a given excipient may fulfill more than one purpose. Examples of types of excipient include permeation enhancers, mucoadhesive polymers, surfactants, thickening agents, gelling polymers, flowability agents, flavoring agents, sweeteners, colorants, palatants, antioxidants, bioavailability enhancers, viscosity modifying agents, tonicity agents, drug carriers, sustained-release agents, comfort-enhancing agents, emulsifiers, solubilizing aids, lubricants, carriers, binders, disintegrants and stabilizing agents. Specific excipients include pectin, rice husks, rice, xanthum gum, gum arabic, beta cyclodextrin, alpha cyclodextrin, microcrystalline cellulose, sorbitol, dextrose, guar gum, acacia gum, cellulose gum, talc, magnesium stearate.
[0045] The term "desired psychoactive effects" herein refers to intended changes in nervous system function resulting in alterations in perception, mood, consciousness, cognition, or behavior that are achieved upon administration of a psychoactive alkaloid composition.
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
[0046] The term "therapeutic" is intended to qualify the amount of active ingredients required in the treatment of a disease or disorder or on the effecting of a clinical endpoint.
[0047] Reference to "treatment" of a patient is intended to include prophylaxis.
Treatment may also be preemptive in nature, i.e., it may include prevention of disease.
Prevention of a disease may involve complete protection from disease, for example as in the case of prevention of infection with a pathogen or may involve prevention of disease progression. For example, prevention of a disease may not mean complete foreclosure of any effect related to the diseases at any level, but instead may mean prevention of the symptoms of a disease to a clinically significant or detectable level.
Prevention of diseases may also mean prevention of progression of a disease to a later stage of the disease.
B. Composition
Treatment may also be preemptive in nature, i.e., it may include prevention of disease.
Prevention of a disease may involve complete protection from disease, for example as in the case of prevention of infection with a pathogen or may involve prevention of disease progression. For example, prevention of a disease may not mean complete foreclosure of any effect related to the diseases at any level, but instead may mean prevention of the symptoms of a disease to a clinically significant or detectable level.
Prevention of diseases may also mean prevention of progression of a disease to a later stage of the disease.
B. Composition
[0048] The embodiments of the vaporizable psychoactive alkaloid composition described herein are in the liquid form, made by combining a psychoactive alkaloid extract, a C2-C4 alcohol or polyol carrier, a fatty acid, a fatty alcohol, an optional antioxidant, optional flavoring, and optionally one or more further excipients. The fatty acid reacts with the alcohol or polyol carrier to form a fatty acid ester. The fatty acid is in excess of the alcohol or polyol, some or all of which are used up in the reaction. The fatty acid also reacts with the fatty alcohol, resulting in a mixture of fatty acid, fatty alcohol, alcohol, polyol and/or fatty acid esters.
[0049] In some embodiments, the psychoactive alkaloid extract has a desired amount of a phosphorylated psychoactive alkaloid and a desired amount of a dephosphorylated psychoactive alkaloid. That is, the proportion of dephosphorylated to phosphorylated alkaloids is controlled. In some embodiments, a majority or all of the alkaloids are dephosphorylated. In some embodiments, the psychoactive alkaloid extract additionally includes other psychoactive alkaloids that are not phosphorylatable. In some embodiments, a synthetic psychoactive alkaloid is used instead of the psychoactive alkaloid extract. In some embodiments, the synthetic psychoactive alkaloid has no phosphorylated alkaloid content, i.e. the alkaloid content is entirely dephosphorylated psychoactive alkaloid.
[0050] The vaporizable compositions allow the delivery of psychoactive alkaloids into the patient's bloodstream while bypassing the gastrointestinal tract and the hepatic Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
metabolism. As such, they result in a higher bioavailability of the dephosphorylated psychoactive alkaloids to the patient compared to ingested forms, which may suffer degradation en route to the bloodstream. This also allows for lower dosage requirements of psychoactive alkaloids to achieve the desired psychoactive effects. Due to the vapor from the vaporizable composition being taken in through the mouth, it is possible but unlikely that some of the psychoactive alkaloid passes into the body through the mucosa lining of the mouth and through the gastrointestinal tract.
PSU005c-PCT
metabolism. As such, they result in a higher bioavailability of the dephosphorylated psychoactive alkaloids to the patient compared to ingested forms, which may suffer degradation en route to the bloodstream. This also allows for lower dosage requirements of psychoactive alkaloids to achieve the desired psychoactive effects. Due to the vapor from the vaporizable composition being taken in through the mouth, it is possible but unlikely that some of the psychoactive alkaloid passes into the body through the mucosa lining of the mouth and through the gastrointestinal tract.
[0051] The vaporizable psychoactive alkaloid composition is vaporized in a vaporizer for oral delivery to the patient or user, who inhales it as a gas, which may include fine droplets if vaporization is incomplete or if there is condensation. An example of a vaporizer is an electronic cigarette, although there are numerous other types of vaporizer that use heat as the energy source for vaporization. The vaporizable psychoactive alkaloid composition described herein can be used, for example, in medical research on the use of psychedelic substances in treatments for mental illnesses.
[0052] The amounts of the components mixed together to form the vaporizable composition are summarized in TABLE 1. The resulting make-up of the composition, due to the reaction of the fatty acid and carrier to produce fatty acid ester, for example, may be different from the make-up of the ingredients as separate components.
Added Component Range / % Example /
%
Psychoactive synthetic or extract 0.1-15 8 Carrier (alcohol/polyol) 5-71.9 60 Fatty acid 20-78.1 20 Fatty alcohol 5-40 10 Antioxidant 0-10 1 Flavoring 0-10 1 B1. Psychoactive component
Added Component Range / % Example /
%
Psychoactive synthetic or extract 0.1-15 8 Carrier (alcohol/polyol) 5-71.9 60 Fatty acid 20-78.1 20 Fatty alcohol 5-40 10 Antioxidant 0-10 1 Flavoring 0-10 1 B1. Psychoactive component
[0053] The psychoactive component is either an extract or synthetic, and may be liquid or solid.
[0054] When it is an extract, it may be obtained from any psychoactive organism, such as a plant, fungus or animal, and the extract may be in solid or liquid form, the liquid form being, for example, a slurry or a solution. In some embodiments, the psychoactive component is a psychoactive alkaloid extract that forms 0.1% to 15% by weight of the Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
composition. In other embodiments, the psychoactive alkaloid extract forms 6%
to 10%
by weight of the composition.
PSU005c-PCT
composition. In other embodiments, the psychoactive alkaloid extract forms 6%
to 10%
by weight of the composition.
[0055] In some embodiments, the psychoactive alkaloid extract has a total psychoactive alkaloid content ranging from 0.1% to 99% by weight of the extract. In other embodiments, the psychoactive alkaloid extract has a total psychoactive alkaloid content ranging from 1% to 75% by weight of the extract. In yet other embodiments, the psychoactive alkaloid extract has a total psychoactive alkaloid content ranging from 10% to 30% by weight of the extract. In other embodiments, the psychoactive alkaloid composition has a total psychoactive alkaloid content ranging from 15.00% to 25.00%
by weight of the composition. The total psychoactive alkaloid content in the psychoactive alkaloid extract may be defined as a percentage up to two decimal places.
by weight of the composition. The total psychoactive alkaloid content in the psychoactive alkaloid extract may be defined as a percentage up to two decimal places.
[0056] In some embodiments, the psychoactive alkaloid extract further includes naturally occurring substances. The naturally occurring substances are present in the psychoactive alkaloid extract in a concentration ranging from 1% to 99.9% by weight.
These naturally occurring substances may have side effects when inhaled as part of the composition. The naturally occurring substances referred to herein include fats, sugars, carbohydrates, chitin, chitosan, minerals, waxes, proteins, or any combination selected therefrom. The concentration range of the naturally occurring substances in the psychoactive alkaloid extract or the purified psychoactive alkaloid extract will vary due to various factors for example, but not limited to, the source of the psychoactive alkaloid extract, the extraction technique used, the efficiency of the extraction process, and the amount of the psychoactive alkaloid in the extract.
These naturally occurring substances may have side effects when inhaled as part of the composition. The naturally occurring substances referred to herein include fats, sugars, carbohydrates, chitin, chitosan, minerals, waxes, proteins, or any combination selected therefrom. The concentration range of the naturally occurring substances in the psychoactive alkaloid extract or the purified psychoactive alkaloid extract will vary due to various factors for example, but not limited to, the source of the psychoactive alkaloid extract, the extraction technique used, the efficiency of the extraction process, and the amount of the psychoactive alkaloid in the extract.
[0057] The psychoactive component includes predominantly dephosphorylated psychoactive alkaloid in comparison to phosphorylated psychoactive alkaloid.
In some embodiments, the desired amount of the dephosphorylated psychoactive alkaloid is over 50% by weight of the total psychoactive alkaloid content in the psychoactive alkaloid extract, and the desired amount of the phosphorylated psychoactive alkaloid is the remainder. In some embodiments, the desired amount of the dephosphorylated psychoactive alkaloid is 100% by weight of the total psychoactive alkaloid content in the psychoactive alkaloid extract. In some embodiments, the desired amount of the dephosphorylated psychoactive alkaloid is 100% by weight of the total phosphorylatable psychoactive alkaloid content in the psychoactive alkaloid extract.
In some embodiments, the desired amount of the dephosphorylated psychoactive alkaloid is over 50% by weight of the total psychoactive alkaloid content in the psychoactive alkaloid extract, and the desired amount of the phosphorylated psychoactive alkaloid is the remainder. In some embodiments, the desired amount of the dephosphorylated psychoactive alkaloid is 100% by weight of the total psychoactive alkaloid content in the psychoactive alkaloid extract. In some embodiments, the desired amount of the dephosphorylated psychoactive alkaloid is 100% by weight of the total phosphorylatable psychoactive alkaloid content in the psychoactive alkaloid extract.
[0058] In some embodiments, the psychoactive alkaloid extract is present in its purified form i.e. as a purified psychoactive alkaloid extract. In some embodiments, the purified Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
psychoactive alkaloid extract has a total psychoactive alkaloid content ranging from 10% to 99% by weight of the purified psychoactive alkaloid extract. The naturally occurring substances are present in the purified psychoactive alkaloid extract in a concentration ranging from 1% to 90% by dry weight. In some embodiments, the purified psychoactive alkaloid extract has a total psychoactive alkaloid content ranging from 10.00% to 30.00% by weight of the purified psychoactive alkaloid extract.
PSU005c-PCT
psychoactive alkaloid extract has a total psychoactive alkaloid content ranging from 10% to 99% by weight of the purified psychoactive alkaloid extract. The naturally occurring substances are present in the purified psychoactive alkaloid extract in a concentration ranging from 1% to 90% by dry weight. In some embodiments, the purified psychoactive alkaloid extract has a total psychoactive alkaloid content ranging from 10.00% to 30.00% by weight of the purified psychoactive alkaloid extract.
[0059] In some embodiments, the desired amount of the dephosphorylated psychoactive alkaloid is over 50% by weight of the total psychoactive alkaloid content in the purified psychoactive alkaloid extract, and the desired amount of the phosphorylated psychoactive alkaloid is the remainder. In some embodiments, the desired amount of the dephosphorylated psychoactive alkaloid is 100% by weight of the total psychoactive alkaloid content in the purified psychoactive alkaloid extract. In some embodiments, the desired amount of the dephosphorylated psychoactive alkaloid is 100% by weight of the total phosphorylatable psychoactive alkaloid content in the purified psychoactive alkaloid extract.
[0060] The composition of the present invention has a total psychoactive alkaloid content present in a specific amount. In some embodiments, the specific amount of the total psychoactive alkaloid content is accurate to one significant figure. In other embodiments, the specific amount of the total psychoactive alkaloid content is accurate to two, three or four significant figures. The presence of the total psychoactive alkaloid content in a specific amount in the composition is possible despite the variation of psychoactive content in different batches of the extract, because the content in each batch is known and the amount of each extract used can be chosen accordingly.
[0061] In some embodiments, the phosphorylated alkaloid is psilocybin, baeocystin, norbaeocystin, aeruginascin, an alkaloid with similar properties, or any combination selected therefrom; and the dephosphorylated alkaloid is psilocin, bufotenine, bufotenidine, norpsilocin, 4-hydroxytryptamine (4-HT), N,N,N-trimethy1-4-hydroxytryptamine, 4-hydroxy-N,N,N-trimethyltryptamine (4-HO-TMT), an alkaloid with similar properties, or any combination selected therefrom.
[0062] In some embodiments, the psychoactive component is a synthetic psychoactive alkaloid component. In some embodiments, the synthetic psychoactive alkaloid component has a psychoactive alkaloid content of up to 99%, and the amount of the synthetic psychoactive alkaloid component is 0.1-15% by weight of the composition. In some embodiments, the amount of synthetic psychoactive alkaloid component is 6-10%
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
by weight of the composition. The psychoactive alkaloid in the synthetic psychoactive alkaloid component may be entirely dephosphorylated psychoactive alkaloid, for example psilocin. In other embodiments, the psychoactive alkaloid in the synthetic psychoactive alkaloid component may be partly dephosphorylated psychoactive alkaloid, for example psilocin and partly phosphorylated, for example psilocybin.
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
by weight of the composition. The psychoactive alkaloid in the synthetic psychoactive alkaloid component may be entirely dephosphorylated psychoactive alkaloid, for example psilocin. In other embodiments, the psychoactive alkaloid in the synthetic psychoactive alkaloid component may be partly dephosphorylated psychoactive alkaloid, for example psilocin and partly phosphorylated, for example psilocybin.
[0063] Where the psychoactive component is in a liquid form, whether an extract or synthetic, the dephosphorylated alkaloid is at its isoelectric point or, in other words, is in its freebase form. Where the dephosphorylated alkaloid is psilocin, the liquid psychoactive component has, for example, a pH of 8.47 0.25, i.e. the isoelectric point of psilocin. Where the psychoactive component is in a powder form, it will have, for example, a pH of 8.47 0.25 if mixed with pure water. When the fatty acid is added to the psychoactive component, the pH of the mixture may be in the range 4-10.
B2. Carrier
B2. Carrier
[0064] The carrier is a C2-C4 alcohol or polyol, individually chosen from or is a mixture of any of ethanol, 1-propanol, isopropyl alcohol, tert-butyl alcohol, glycerine, polyethylene glycol (PEG) and propylene glycol (PG). In some embodiments, the amount of carrier put into the composition is 5-71.9% by weight of the composition. The upper limit is based on the requirement to have at least the specified minimum quantities of other components. The lower limit represents the requirement to have at least some alcohol and/or polyol in the composition in order to form the fatty acid ester(s). In some embodiments, the amount of carrier added is 50-70% by weight of the composition. In some embodiments, the amount of carrier added is 60% by weight of the composition. The carrier may, but not always, form the majority of the vaporizable composition. Furthermore, it serves to react with the fatty acid to create fatty acid ester in the composition. The fatty acid ester helps with the vaporization of the composition and also provides stability to the composition.
B3. Fatty acid
B3. Fatty acid
[0065] In some embodiments, the fatty acid introduced into the composition is 78.1% by weight of the composition. If there is too little fatty acid, the quantity of fatty acid ester in the composition will be too low to aid with vaporization. If there is too much fatty acid, vaporization will be hindered. In other embodiments, the amount of fatty acid added to the composition is 20% by weight of the composition. The fatty acid is Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
individually chosen from, or is a mixture of any of, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, ascorbyl palmitate, cetyl palmitate, colfosceril palmitate, ehtylhexyl palmitate, isopropyl palmitate, palmitoyl-CoA, retinyl palmitate and sucrose monopalmitate. The fatty acid reacts with the carrier to produce fatty acid ester in the composition.
B4. Fatty alcohol
PSU005c-PCT
individually chosen from, or is a mixture of any of, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, ascorbyl palmitate, cetyl palmitate, colfosceril palmitate, ehtylhexyl palmitate, isopropyl palmitate, palmitoyl-CoA, retinyl palmitate and sucrose monopalmitate. The fatty acid reacts with the carrier to produce fatty acid ester in the composition.
B4. Fatty alcohol
[0066] The composition includes a fatty alcohol, which acts as an adsorption enhancer in the mucosa of the mouth and lungs. The amount of fatty alcohol added to the composition is 5-40% by weight of the composition. If the amount of fatty alcohol is too low, then there may be insufficient formation of the beneficial fatty acid esters. It is not detrimental, however, if the amount of fatty alcohol is too high. In some embodiments, the fatty alcohol is added to the composition in a concentration of 8-12% by weight of the composition.
[0067] The fatty alcohol is individually chosen from or is a mixture of any of capryl alcohol (1-octanol), 2-ethyl hexanol, pelargonic alcohol (1-nonanol), capric alcohol (1-decanol, decyl alcohol), undecyl alcohol (1-undecanol, undecanol, hendecanol), lauryl alcohol (dodecanol, 1-dodecanol), tridecyl alcohol (1-tridecanol, tridecanol, isotridecanol), myristyl alcohol (1-tetradecanol), pentadecyl alcohol (1-pentadecanol, pentadecanol), cetyl alcohol (1-hexadecanol), palmitoleyl alcohol (cis-9-hexadecen-1-01), heptadecyl alcohol (1-n-heptadecanol, heptadecanol), stearyl alcohol (1-octadecanol), isostearyl alcohol (16-methylheptadecan-1-ol), elaidyl alcohol (9E-octadecen-1-ol), oleyl alcohol (cis-9-octadecen-1-ol), linoleyl alcohol (9Z,12Z-octadecadien-1-ol), elaidolinoleyl alcohol (9E,12E-octadecadien-1-ol), linolenyl alcohol (9Z,12Z,15Z-octadecatrien-1-ol), elaidolinolenyl alcohol (9E,12E,15-E-octadecatrien-1-ol), ricinoleyl alcohol (12-hydroxy-9-octadecen-1-ol), nonadecyl alcohol (1-nonadecanol), arachidyl alcohol (1-eicosanol), heneicosyl alcohol (1-heneicosanol), behenyl alcohol (1-docosanol), erucyl alcohol (cis-13-docosen-1-ol), lignoceryl alcohol (1-tetracosanol), ceryl alcohol (1-hexacosanol), 1-heptacosanol, montanyl alcohol, cluytyl alcohol (1-octacosanol), 1-nonacosanol, myricyl alcohol, melissyl alcohol (1-triacontanol), 1-dotriacontanol, and geddyl alcohol (1-tetratriacontanol). In other embodiments it is possible to include one or more fatty alcohols other than these.
B5. Antioxidant Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
B5. Antioxidant Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
[0068] The antioxidant is optionally present in the composition in a concentration of about 0-10% by weight of the composition. The antioxidant provides chemical stability to the composition so that it has a longer shelf life compared to compositions without the antioxidant. The amount of antioxidant should be added in sufficient quantity to provide stability to the composition.
[0069] The antioxidant is individually chosen from or is a mixture of any of citric acid, butylated hydroxytoluene, ascorbic acid, glutathione, retinol, a-tocopherol, [3-carotene, a-carotene, ubiquinone, butylated hydroxyanisole, ethylenediaminetetraacetic acid, selenium, zinc, lignan, uric acid, lipoic acid, N-acetylcysteine and ascorbic acid.
[0070] The particular choice of antioxidant should be compatible with the selected carrier. For example, ascorbic acid will only be soluble in polar solvents, whereas tocopherol will be more soluble in non-polar solvents.
B6. Flavoring
B6. Flavoring
[0071] The composition optionally includes a flavorant amounting to 0-10% of the composition by weight. The flavoring may be menthol, a sweetener or both menthol and a sweetener, for example. Other flavorants that are suitable for inhalation may also be used in the composition. The flavorant may be natural or synthetic.
B7. Bioavailability enhancer
B7. Bioavailability enhancer
[0072] Optionally, in some embodiments, the composition includes a bioavailability enhancer. Bioavailability enhancers bind to active pharmaceutical ingredients and either increase their stability, ability to cross membranes, or prevent the body from breaking down the API. In one embodiment, the bioavailability enhancer is present in the composition in a concentration ranging up to 5% by weight of the composition.
In another embodiment, the bioavailability enhancer is present in the composition in a concentration ranging from 0.5-2% by weight of the composition. Utilization of bioavailability enhancers in these relatively small concentrations decreases the occurrence of an adverse effect, and only small concentrations are needed to be effective. Examples of bioavailability enhancer include, but are not limited to, beta cyclodextrin, alpha cyclodextrin, piperine, citric acid, and beta-carbolines (MA01) such as harmaline.
In another embodiment, the bioavailability enhancer is present in the composition in a concentration ranging from 0.5-2% by weight of the composition. Utilization of bioavailability enhancers in these relatively small concentrations decreases the occurrence of an adverse effect, and only small concentrations are needed to be effective. Examples of bioavailability enhancer include, but are not limited to, beta cyclodextrin, alpha cyclodextrin, piperine, citric acid, and beta-carbolines (MA01) such as harmaline.
[0073] The particular choice of bioavailability enhancer should be made based on its compatibility with the carrier. Bioavailability enhancers may work by different Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
mechanisms. For example, all of them except the beta carbolines work by chelating or enhancing adsorption in the mucosa. The beta carbolines will prevent or reduce breakdown of psilocin in vivo.
C. Extraction with dephosphorylation control
PSU005c-PCT
mechanisms. For example, all of them except the beta carbolines work by chelating or enhancing adsorption in the mucosa. The beta carbolines will prevent or reduce breakdown of psilocin in vivo.
C. Extraction with dephosphorylation control
[0074] In one embodiment, referring to FIG. 1, a process for obtaining a psychoactive alkaloid extract with dephosphorylation control, according to an embodiment of the present invention, is shown. Dephosphorylation applies to the psychoactive alkaloids that are phosphorylatable.
[0075] The process includes step 10 of obtaining powdered biomass from a psychoactive alkaloid source, such as a psychoactive organism. The powdered biomass is obtained by drying and pulverizing the psychoactive alkaloid source. The drying is carried out via vacuum desiccation, freeze drying, timed forced air drying, or other suitable drying method known to a person of skill in the art, to obtain a dried biomass. The pulverization is carried out by milling, grinding, or other method to reduce the particle size of the dried biomass.
[0076] In one embodiment, the drying is carried out in a forced air oven completely shielded from all light at 20-30 C for a time period of 5-10 hours. However, there is room for optimization of the drying step, using different temperatures (e.g.
10 ¨ 50 C) and different durations.
10 ¨ 50 C) and different durations.
[0077] In one embodiment, the psychoactive alkaloid source is a mushroom from the genus Conocybe, Copelandia, Galerina, Gymnopilus, Inocybe, Panaeolus, Pholiotina, Pluteus or Psilocybe, or any combination of mushrooms selected therefrom. In some embodiments, gills, caps, stems, or the whole of the fungi is used as the alkaloid source. In other embodiments, the psychoactive alkaloid source is another organism, such as another fungus, a plant or an animal.
[0078] Step 12 involves extracting the psychoactive alkaloid from the dried powdered biomass with an acidified solvent or a basified solvent to obtain a psychoactive alkaloid liquid with a specific pH, wherein the specific pH is 3.5 or lower, or 10.5 or higher.
[0079] When used, the acid in step 12 may be acetic acid, adipic acid, ascorbic acid, ammonium aluminum sulphate, ammonium citrate dibasic, ammonium citrate monobasic, calcium citrate, calcium fumarate, calcium gluconate, calcium phosphate dibasic, calcium phosphate monobasic, hydrochloric acid, sulphuric acid monobasic, calcium phosphate tribasic, citric acid, fumaric acid, gluconic acid, magnesium Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
fumarate, malic acid, phosphoric acid, potassium acid tartrate, potassium citrate, potassium fumarate, sodium citrate, sodium fumarate, sodium gluconate, sodium lactate, sodium potassium hexametaphosphate, sodium potassium tartrate, sodium potassium tripolyphosphate, sodium pyrophosphate tetrabasic, sodium tripolyphosphate, tartaric acid, and any combination of one or more of these.
In some embodiments, the acid is either only hydrochloric acid or only phosphoric acid, for example. It is also envisaged that other acids may be used, for example non-food-grade acids that may be used by pharmaceuticals.
PSU005c-PCT
fumarate, malic acid, phosphoric acid, potassium acid tartrate, potassium citrate, potassium fumarate, sodium citrate, sodium fumarate, sodium gluconate, sodium lactate, sodium potassium hexametaphosphate, sodium potassium tartrate, sodium potassium tripolyphosphate, sodium pyrophosphate tetrabasic, sodium tripolyphosphate, tartaric acid, and any combination of one or more of these.
In some embodiments, the acid is either only hydrochloric acid or only phosphoric acid, for example. It is also envisaged that other acids may be used, for example non-food-grade acids that may be used by pharmaceuticals.
[0080] When used, the base in step 12 may be ammonium bicarbonate, ammonium carbonate, ammonium hydroxide, calcium acetate, calcium carbonate, calcium chloride, calcium hydroxide, calcium lactate, calcium oxide, calcium phosphate dibasic, calcium phosphate monobasic, magnesium carbonate, potassium aluminum sulphate, potassium bicarbonate, potassium carbonate, potassium hydroxide, potassium lactate, potassium phosphate dibasic, potassium pyrophosphate tetrabasic, potassium phosphate tribasic, potassium tripolyphosphate, sodium acetate, sodium acid pyrophosphate, sodium aluminum phosphate, sodium aluminum sulphate, sodium bicarbonate, sodium bisulphate, sodium carbonate, sodium hexametaphosphate, sodium hydroxide, sodium lactate, sodium phosphate dibasic, sodium phosphate monobasic, sodium phosphate tribasic or any combination therefrom. In one embodiment, the base is solely sodium hydroxide, for example. Other bases may be used in other embodiments, for example non-food-grade bases that may be used by pharmaceuticals.
[0081] In some embodiments, the acidified solvent is a mixture of an acid and a C1-C4 primary aliphatic alcohol, a C3-C4 ketone, water, or any combination selected therefrom. The acid may be, for example, citric acid, ascorbic acid, formic acid, acetic acid, hydrochloric acid, phosphoric acid, sulphuric acid, or any combination selected therefrom. In other embodiments, the basified solvent is a mixture of a base and a C1-C4 primary aliphatic alcohol, a C3-C4 ketone, water, or any combination selected therefrom. The base may be, for example, sodium hydroxide, potassium hydroxide, ammonium hydroxide, sodium bicarbonate, calcium carbonate, or any combination selected therefrom.
[0082] After adding the acidified solvent, if the acidified solvent used, the psychoactive alkaloid liquid has a pH ranging from 0.5-3.5. In an exemplary embodiment, the pH of the psychoactive alkaloid liquid obtained after addition of the acidified solvent is 2. The Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
pH is adjusted to lower than 3.5 in the extraction step 12 to promote the conversion of phosphorylated psychoactive alkaloid to dephosphorylated psychoactive alkaloid, thus allowing the preparation of the psychoactive alkaloid liquid with the predominantly or entirely dephosphorylated psychoactive alkaloid. For example, with pH
conditions lower than 3.5, psilocybin is readily converted to psilocin. In some embodiments, during the extraction step the psychoactive alkaloid liquid has a pH lower than 3.5 and the desired amount of the phosphorylated psychoactive alkaloid is 0% by weight of the total psychoactive alkaloid content in the psychoactive alkaloid extract. The desired amount of the dephosphorylated psychoactive alkaloid is 100% by weight of the total psychoactive alkaloid content in the psychoactive alkaloid extract. Even with neutral hydroethanol extraction, a large portion of psilocybin may be converted to psilocin.
However, the low pH environment (<3.5) protects the psilocin from oxidation.
PSU005c-PCT
pH is adjusted to lower than 3.5 in the extraction step 12 to promote the conversion of phosphorylated psychoactive alkaloid to dephosphorylated psychoactive alkaloid, thus allowing the preparation of the psychoactive alkaloid liquid with the predominantly or entirely dephosphorylated psychoactive alkaloid. For example, with pH
conditions lower than 3.5, psilocybin is readily converted to psilocin. In some embodiments, during the extraction step the psychoactive alkaloid liquid has a pH lower than 3.5 and the desired amount of the phosphorylated psychoactive alkaloid is 0% by weight of the total psychoactive alkaloid content in the psychoactive alkaloid extract. The desired amount of the dephosphorylated psychoactive alkaloid is 100% by weight of the total psychoactive alkaloid content in the psychoactive alkaloid extract. Even with neutral hydroethanol extraction, a large portion of psilocybin may be converted to psilocin.
However, the low pH environment (<3.5) protects the psilocin from oxidation.
[0083] If the pH in step 12 were 10.5 or higher, then the conversion of phosphorylated alkaloids to dephosphorylated alkaloids would be inhibited, and the result would be predominantly or entirely phosphorylated alkaloids. This may be limited by the initial amount of alkaloids in the psychoactive alkaloid source that were already dephosphorylated. As predominantly dephosphorylated alkaloids are more useful in the vaporizable composition than phosphorylated alkaloids, then the acidified solvent would be chosen in step 12.
[0084] In some embodiments, the extraction is performed at a temperature ranging from 5-95 C. In other embodiments, the extraction is performed at a temperature ranging from 50-75 C. In other embodiments, the extraction is performed at room temperature.
[0085] In some embodiments, the extraction is performed for a time period ranging from 10-720 minutes. For most cases, a time below 10 min would result in a mostly incomplete yield, and above 720 min the extraction may be incomplete but would be continuing at a negligible rate. In another embodiment, and more usually, the extraction is performed for a time period ranging from 30-240 minutes.
[0086] In some embodiments, the extraction is performed at an applied pressure ranging from 50kPa to 140MPa (7 to 20,000 psi). In yet another embodiment, the extraction is performed at a pressure ranging from 70kPa to 140kPa (10 to 20 psi).
Application of pressure may be used to increase the rate of extraction.
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
Application of pressure may be used to increase the rate of extraction.
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
[0087] In some embodiments, the extraction is performed with a solvent to solid ratio in the range 1L:1kg to 50L:1kg, wherein the solid is the dried powdered biomass.
In one embodiment, the extraction is performed with a solvent to solid ratio of 20L:1kg.
In one embodiment, the extraction is performed with a solvent to solid ratio of 20L:1kg.
[0088] After the addition of the acidified solvent or the basified solvent, the powered biomass and the solvent may be mixed, continually or intermittently during the extraction, followed by step 14 of filtration to result in an extracted filtrate (i.e.
psychoactive alkaloid liquid).
psychoactive alkaloid liquid).
[0089] In step 18 of the process, the pH of the obtained psychoactive alkaloid liquid is adjusted to a pH ranging from 3.5-4.5. The pH is adjusted by adding a base or an acid.
The pH is adjusted to a value in this range as the psychoactive alkaloid liquid exhibits a good anti-microbial stability in this pH range. Also, there is no conversion (or further conversion, as the case may be) of phosphorylated alkaloids to dephosphorylated alkaloids at this pH after the alkaloids are removed from the biomass, which points to enzymatic hydrolysis being responsible for conversion in the source of the psychoactive alkaloids. In exemplary embodiments for step 18, the base is sodium hydroxide and the acid is citric acid. Any other appropriate acid or base can be used to adjust the pH, which a person of skill in the art may determine. The selection of the acid or the base will depend upon the nature of the pH of the psychoactive alkaloid liquid prior to adjusting it to the range of 3.5-4.5.
The pH is adjusted to a value in this range as the psychoactive alkaloid liquid exhibits a good anti-microbial stability in this pH range. Also, there is no conversion (or further conversion, as the case may be) of phosphorylated alkaloids to dephosphorylated alkaloids at this pH after the alkaloids are removed from the biomass, which points to enzymatic hydrolysis being responsible for conversion in the source of the psychoactive alkaloids. In exemplary embodiments for step 18, the base is sodium hydroxide and the acid is citric acid. Any other appropriate acid or base can be used to adjust the pH, which a person of skill in the art may determine. The selection of the acid or the base will depend upon the nature of the pH of the psychoactive alkaloid liquid prior to adjusting it to the range of 3.5-4.5.
[0090] In some embodiments, the extraction includes further extracting the psychoactive alkaloid by repeating the extraction step. Filtrate residue from step 14 is collected and to this filtrate residue, the same or a different acidified solvent, or the same or a different basified solvent is added, as in step 12. The resulting mixture is mixed and followed by filtration to obtain another filtrate. This filtrate and the previous filtrate are mixed together to result in a bulk or pooled filtrate. To this bulk filtrate the acid or the base is added to adjust the pH to 3.5-4.5 according to step 18. In some embodiments, the further extraction of the filtrate obtained after extraction with the acidified or the basified solvent is repeated until a required amount of the phosphorylated psychoactive alkaloid and/or the dephosphorylated psychoactive alkaloid is extracted. The number of extraction cycles to be repeated will depend on various variable factors such as the source of the psychoactive alkaloid and the solubility of the psychoactive alkaloid in the acidified or the basified solvent.
[0091] Step 20 of the process involves evaporating the solvent from the psychoactive alkaloid liquid (i.e. the filtrate or bulk filtrate) to obtain the psychoactive alkaloid extract Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
with the desired amount of the phosphorylated psychoactive alkaloid and the desired amount of the dephosphorylated psychoactive alkaloid. The solvent is completely or partially evaporated to result in the psychoactive alkaloid extract as a slurry or powder.
The evaporation is carried out by methods such as air-drying, rotary evaporation, or other methods known in the art to suitably evaporate solvent from psychoactive alkaloid liquid. At this point in time, away from the biomass, dephosphorylated/phosphorylated alkaloids are fairly heat resistant, more so under vacuum, and so rotary evaporation, for example, is a suitable process.
PSU005c-PCT
with the desired amount of the phosphorylated psychoactive alkaloid and the desired amount of the dephosphorylated psychoactive alkaloid. The solvent is completely or partially evaporated to result in the psychoactive alkaloid extract as a slurry or powder.
The evaporation is carried out by methods such as air-drying, rotary evaporation, or other methods known in the art to suitably evaporate solvent from psychoactive alkaloid liquid. At this point in time, away from the biomass, dephosphorylated/phosphorylated alkaloids are fairly heat resistant, more so under vacuum, and so rotary evaporation, for example, is a suitable process.
[0092] Evaporation step 20 may be paused, for standardization in step 21, and continued after standardization. The evaporation of a portion of the solvent, before collection of the psychoactive alkaloid extract, in slurry form, for standardization, is done to obtain a quantity of a psychoactive alkaloid extract slurry that is easy to handle in the subsequent steps of the standardization process. The quantity of the portion of the solvent to be evaporated before pausing the evaporation is not so much as to make it too viscous to handle well. The quantity of the portion of the solvent to be evaporated will depend on various factors, for example, but not limited to, the contents of the psychoactive alkaloid liquid and the quantity of the psychoactive alkaloid liquid present at the beginning of the evaporation step.
[0093] For the purposes of the vaporizable composition disclosed herein, the desired amount of the dephosphorylated psychoactive alkaloid is generally chosen to be 100%
of the total phosphorylatable psychoactive alkaloid content in the psychoactive alkaloid extract, and the desired amount of the phosphorylated psychoactive alkaloid is 0%. As such, an acidified solvent is selected in step 12. However, it is conceivable that a vaporizable composition with 100% or predominantly phosphorylated psychoactive alkaloids may be made for the purposes of study or other uses, in which case a basified solvent is chosen in step 12.
D. Purification
of the total phosphorylatable psychoactive alkaloid content in the psychoactive alkaloid extract, and the desired amount of the phosphorylated psychoactive alkaloid is 0%. As such, an acidified solvent is selected in step 12. However, it is conceivable that a vaporizable composition with 100% or predominantly phosphorylated psychoactive alkaloids may be made for the purposes of study or other uses, in which case a basified solvent is chosen in step 12.
D. Purification
[0094] In one embodiment, referring to FIG. 2, steps of a process for obtaining a purified psychoactive alkaloid extract are shown. The main steps are:
adsorbing, in step 34, the psychoactive alkaloid extract obtained in step 18 or 20 (without standardization) onto a resin to obtain an adsorbed psychoactive alkaloid, which may include one or more adsorbed psychoactive alkaloids; eluting, in step 38, the adsorbed psychoactive Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
alkaloid using a solvent to obtain a purified psychoactive alkaloid solution;
and evaporating, in step 42, the solvent from the purified psychoactive alkaloid solution.
adsorbing, in step 34, the psychoactive alkaloid extract obtained in step 18 or 20 (without standardization) onto a resin to obtain an adsorbed psychoactive alkaloid, which may include one or more adsorbed psychoactive alkaloids; eluting, in step 38, the adsorbed psychoactive Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
alkaloid using a solvent to obtain a purified psychoactive alkaloid solution;
and evaporating, in step 42, the solvent from the purified psychoactive alkaloid solution.
[0095] In one embodiment, the psychoactive alkaloid extract obtained in step 18 or 20 is followed by completely or partially concentrating the obtained psychoactive alkaloid extract by evaporation of the solvent from the extract in step 22. If the solvent from the extract has been completely evaporated in step 22, then reverse osmosis water, more solvent or another solvent is added back. Other water may be used in place of reverse osmosis water, which is usually selected for its purity.
[0096] In some embodiments, the process includes adding, in step 26, an acid or a base to the psychoactive alkaloid extract obtained in step 20 to obtain a psychoactive alkaloid solution with a desired pH.
[0097] When used, the acid may be acetic acid, adipic acid, ascorbic acid, ammonium aluminum sulphate, ammonium citrate dibasic, ammonium citrate monobasic, calcium citrate, calcium fumarate, calcium gluconate, calcium phosphate dibasic, calcium phosphate monobasic, hydrochloric acid, sulphuric acid monobasic, calcium phosphate tribasic, citric acid, fumaric acid, gluconic acid, magnesium fumarate, malic acid, phosphoric acid, potassium acid tartrate, potassium citrate, potassium fumarate, sodium citrate, sodium fumarate, sodium gluconate, sodium lactate, sodium potassium hexametaphosphate, sodium potassium tartrate, sodium potassium tripolyphosphate, sodium pyrophosphate tetrabasic, sodium tripolyphosphate, tartaric acid, and any combination of one or more of these. In some embodiments, the acid is either only hydrochloric acid or only phosphoric acid, for example. It is also envisaged that other acids may be used.
[0098] When used, the base may be ammonium bicarbonate, ammonium carbonate, ammonium hydroxide, calcium acetate, calcium carbonate, calcium chloride, calcium hydroxide, calcium lactate, calcium oxide, calcium phosphate dibasic, calcium phosphate monobasic, magnesium carbonate, potassium aluminum sulphate, potassium bicarbonate, potassium carbonate, potassium hydroxide, potassium lactate, potassium phosphate dibasic, potassium pyrophosphate tetrabasic, potassium phosphate tribasic, potassium tripolyphosphate, sodium acetate, sodium acid pyrophosphate, sodium aluminum phosphate, sodium aluminum sulphate, sodium bicarbonate, sodium bisulphate, sodium carbonate, sodium hexametaphosphate, sodium hydroxide, sodium lactate, sodium phosphate dibasic, sodium phosphate monobasic, sodium phosphate tribasic or any combination therefrom. In one Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
embodiment, the base is solely sodium hydroxide, for example. Other bases may be used in other embodiments.
PSU005c-PCT
embodiment, the base is solely sodium hydroxide, for example. Other bases may be used in other embodiments.
[0099] In some embodiments, the desired pH psychoactive alkaloid solution has a pH
ranging from 2.5-4.5, or from 9-10. In other embodiments, the desired pH
psychoactive alkaloid solution has a pH of 3, 4, or 9.5. A person of skill in the art will appreciate that the selection of the pH is chosen in a manner to allow for the efficient adsorption of the psychoactive alkaloids onto the resin(s).
ranging from 2.5-4.5, or from 9-10. In other embodiments, the desired pH
psychoactive alkaloid solution has a pH of 3, 4, or 9.5. A person of skill in the art will appreciate that the selection of the pH is chosen in a manner to allow for the efficient adsorption of the psychoactive alkaloids onto the resin(s).
[0100] In one embodiment, the process includes adding phosphoric acid to the psychoactive alkaloid extract to achieve a pH of 4. In another embodiment, the process includes adding hydrochloric acid to the psychoactive alkaloid extract to achieve a pH of 3. In yet another embodiment, the process includes adding sodium hydroxide to the psychoactive alkaloid extract to achieve a pH of 9.5.
[0101] The process includes, in step 30, optionally filtering, centrifuging, or clarifying the psychoactive alkaloid solution or desired pH psychoactive alkaloid solution, as the case may be, and utilizing the obtained filtrate for the following step of adsorption.
Clarifying may be performed, for example, by adding an agglomeration agent. In step 34, the process involves adsorbing the psychoactive alkaloid(s) in the solution onto the resin to obtain an adsorbed psychoactive alkaloid. This may be done, for example, by contacting the psychoactive alkaloid solution with the resin or otherwise treating the psychoactive alkaloid solution with the resin.
Clarifying may be performed, for example, by adding an agglomeration agent. In step 34, the process involves adsorbing the psychoactive alkaloid(s) in the solution onto the resin to obtain an adsorbed psychoactive alkaloid. This may be done, for example, by contacting the psychoactive alkaloid solution with the resin or otherwise treating the psychoactive alkaloid solution with the resin.
[0102] In some embodiments, the resin used in step 34 is an adsorbent resin of the macroporous type, such as, a cation or anion ion-exchange resin, a non-ionic resin, or any combination therefrom. Representative pharmaceutical, nutraceutical or food-grade grade resins for use in accordance with the present invention are known to those skilled in the art. For example, pharmaceutical grade non-ionic macroporous resins are commercially available, e.g. Amberlite XAD4. In some embodiments, the resin is a cationic ion-exchange resin or an anionic-exchange resin. The cationic ion-exchange resin may be selected from commercially available cationic ion-exchange resins known in the art, including but not limited to Amberlite MAC-3 H. The cationic ion-exchange resin may be in an H+ form or an Na + form. The anionic ion-exchange resin may be selected from commercially available anion exchange resins known in the art, including but not limited to Amberchrom 50WX8. The anionic ion-exchange resin may be in an OH- form or a Cl- form. The resins used may be of any particle size. In some embodiments, the resins may be gel type resins, with any size of gel bead.
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
[0103] In step 36, the process involves washing the resin to remove adsorbed impurities from the resin. While not all the impurities are adsorbed onto the resin, some of them may be. The washing step, substantially, does not remove the adsorbed psychoactive alkaloids. The washing solvent may be 100% ethanol, 100% reverse osmosis water, or any other washing solvent used in ion-exchange resin chromatography, provided that the washing removes impurities or by-products that are adsorbed on the resin. Impurities or by-products may include, for example, sugars, carbohydrates, chitin, chitosan, fats, minerals, waxes, or proteins. There may be one, two or more washing steps depending on the embodiment, and the same or different washing solvents may be used for each wash. In other embodiments, the solvent(s) for washing may include a primary aliphatic alcohol, a ketone, water, and any combination therefrom. In one embodiment, the primary aliphatic alcohol is a C1-4 alcohol.
In one embodiment, the primary aliphatic alcohol is 5% ethanol. In one embodiment, the primary aliphatic alcohol is ethanol. In one embodiment, the ketone is a C3-4 ketone. In yet another embodiment, the water is selected from deionized, distilled, reverse osmosis, or otherwise purified water that is substantially without free ions.
In one embodiment, the primary aliphatic alcohol is 5% ethanol. In one embodiment, the primary aliphatic alcohol is ethanol. In one embodiment, the ketone is a C3-4 ketone. In yet another embodiment, the water is selected from deionized, distilled, reverse osmosis, or otherwise purified water that is substantially without free ions.
[0104] After the washing, the process involves eluting, in step 38, the adsorbed psychoactive alkaloid from the resin using a solvent to obtain a purified psychoactive alkaloid solution. The solvent may be an organic solvent, an acid, a base, or water, a combination of an organic solvent and a base, or a combination of an organic solvent and an acid, a combination of an organic solvent and water, a combination of water and a base, or combination of water and an acid. The result of the elution step is a purified psychoactive alkaloid solution. Usually, the solvent is different from the solvent in which the extract is initially provided, and is either a different type of solvent or a different composition of solvent. It may be at a different temperature than the initial solvent.
[0105] In some embodiments, the solvent used in the elution step 38 may be a primary aliphatic alcohol, a ketone, water, and any combination therefrom. In one embodiment, the primary aliphatic alcohol is a C1-4 alcohol. In one embodiment, the primary aliphatic alcohol is 5% ethanol. In one embodiment, the primary aliphatic alcohol is ethanol. In one embodiment, the ketone is a C3-4 ketone. In yet another embodiment, the water is deionized, distilled, reverse osmosis, or otherwise purified water, which is substantially without free ions. In other embodiments, the water is not purified.
[0106] In one embodiment, the solvent used in the elution step 38 is a combination of an organic solvent and an acid. In one embodiment, the combination of an acid and an Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
organic solvent is 2% hydrochloric acid and 80% ethanol, for example. In general, any acidic environment will displace some of the ions from the resin, but the rate and optimization of desorption will be affected by the acid concentration. In one embodiment, the solvent used in the elution step 38 is a combination of an organic solvent and a base. In one embodiment, the combination of an organic solvent and a base is of 2% sodium chloride and 80% ethanol, for example. In general, any basic environment will displace some of the ions from the resin, but the rate and optimization of desorption will be affected by the concentration of the base.
PSU005c-PCT
organic solvent is 2% hydrochloric acid and 80% ethanol, for example. In general, any acidic environment will displace some of the ions from the resin, but the rate and optimization of desorption will be affected by the acid concentration. In one embodiment, the solvent used in the elution step 38 is a combination of an organic solvent and a base. In one embodiment, the combination of an organic solvent and a base is of 2% sodium chloride and 80% ethanol, for example. In general, any basic environment will displace some of the ions from the resin, but the rate and optimization of desorption will be affected by the concentration of the base.
[0107] All the above solvents and combinations thereof are suitable for the elution step because all of the psychoactive alkaloids of interest are soluble therein and, depending on the choice of resin, they are all capable of pulling the alkaloids of interest off a resin.
There are many different resins available, and it is a straightforward matter to select a suitable resin and elution solvent pair.
There are many different resins available, and it is a straightforward matter to select a suitable resin and elution solvent pair.
[0108] In one embodiment, the elution step is carried out at a temperature in the range of 4-75 C. These temperatures are limited by the boiling point of the solvent used, as well as the specifications of allowable food-grade resins, as determined by the manufacturers of the resins and governmental food and drug administrations. In another embodiment, the elution step is carried out at room temperature for convenience, i.e. at 21-25 C.
[0109] Optionally, the purified psychoactive alkaloid solution obtained after elution is further purified by filtering, in step 39, the obtained purified psychoactive alkaloid solution to obtain a filtrate, and then repeating at least steps 34 and 38 with the obtained filtrate. Steps 34 and 38 can be repeated with the same or a different resinous material and the same or a different solvent to obtain a further or twice-purified psychoactive alkaloid solution.
[0110] The result of the elution is a purified psychoactive alkaloid solution.
In one embodiment, the purified psychoactive alkaloid solution has a concentration of 0.07%
by weight of a psychoactive alkaloid, which is the concentration before removal of some or all of the solvent. This concentration may be different in other embodiments, depending on the amount solvent used for the elution and the potency of the raw materials. In one embodiment, the purified psychoactive alkaloid solution is concentrated by evaporating the solvent to form a purified psychoactive slurry that has at least of 5% by weight or more of psychoactive alkaloid. In another embodiment, the resulting purified psychoactive alkaloid slurry has 5-68% by weight of psychoactive Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
alkaloid. In yet other embodiments, the purified psychoactive alkaloid slurry has a concentration of psychoactive alkaloid outside these ranges, and, when dried, can be as low as 0.1% or as high as 99% dry wt/wr/o.
In one embodiment, the purified psychoactive alkaloid solution has a concentration of 0.07%
by weight of a psychoactive alkaloid, which is the concentration before removal of some or all of the solvent. This concentration may be different in other embodiments, depending on the amount solvent used for the elution and the potency of the raw materials. In one embodiment, the purified psychoactive alkaloid solution is concentrated by evaporating the solvent to form a purified psychoactive slurry that has at least of 5% by weight or more of psychoactive alkaloid. In another embodiment, the resulting purified psychoactive alkaloid slurry has 5-68% by weight of psychoactive Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
alkaloid. In yet other embodiments, the purified psychoactive alkaloid slurry has a concentration of psychoactive alkaloid outside these ranges, and, when dried, can be as low as 0.1% or as high as 99% dry wt/wr/o.
[0111] Following the elution, a further washing step 40 may be employed using 100%
ethanol, for example, to wash the resin. This may be considered to be a cleaning step, to refresh the resin and make it ready to be used again in a subsequent step or in another process. In other embodiments, the solvent for further washing may be a primary aliphatic alcohol, a ketone, water, and any combination therefrom. In one embodiment, the primary aliphatic alcohol is a C1-4 alcohol. In one embodiment, the primary aliphatic alcohol is 5% ethanol. In one embodiment, the ketone is a C3-ketone. In yet another embodiment, the water is selected from deionized, distilled, reverse osmosis, or otherwise purified water that is substantially without free ions.
ethanol, for example, to wash the resin. This may be considered to be a cleaning step, to refresh the resin and make it ready to be used again in a subsequent step or in another process. In other embodiments, the solvent for further washing may be a primary aliphatic alcohol, a ketone, water, and any combination therefrom. In one embodiment, the primary aliphatic alcohol is a C1-4 alcohol. In one embodiment, the primary aliphatic alcohol is 5% ethanol. In one embodiment, the ketone is a C3-ketone. In yet another embodiment, the water is selected from deionized, distilled, reverse osmosis, or otherwise purified water that is substantially without free ions.
[0112] After elution step 38, the obtained purified psychoactive alkaloid solution undergoes the evaporation step 42 to completely or partially evaporate the solvents and result in the purified psychoactive alkaloid extract (slurry or powder form).
[0113] Step 42 involves evaporating the solvent from the purified psychoactive alkaloid solution to obtain the purified psychoactive alkaloid extract with, if dephosphorylation control has been used, the desired amount of the phosphorylated psychoactive alkaloid and the desired amount of the dephosphorylated psychoactive alkaloid (for example, 0% and 100% respectively for the composition herein). The solvent is completely or partially evaporated to result in the psychoactive alkaloid extract (slurry or powder respectively). The evaporation is carried out by methods such as air-drying, rotary evaporation, or other methods known in the art to suitably evaporate solvent from psychoactive alkaloid liquid.
[0114] Evaporation in step 42 may be paused, for standardization in step 43, and continued after standardization. The evaporation of a portion of the solvent, before collection of the purified psychoactive alkaloid slurry for standardization, is done to obtain a quantity of a psychoactive alkaloid slurry that is easy to handle in the subsequent steps of the standardization process. The quantity of the portion of the solvent to be evaporated before pausing the evaporation is not so much as to make it too viscous to handle well. The quantity of the portion of the solvent to be evaporated will depend on various factors, for example, but not limited to, the contents of the psychoactive alkaloid solution and the quantity of the psychoactive alkaloid solution present at the beginning of the evaporation step.
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
E. Standardization
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
E. Standardization
[0115] Standardization may be carried out part way through evaporation step 20 (FIG.
1) or evaporation step 42 (FIG. 2), or it may be done after either of these steps.
Standardization is more conveniently done when the extract is a slurry than a powder, but it is not necessary that it is a slurry. Firstly, for example for a slurry, the weight percentage of the psychoactive alkaloids in the psychoactive alkaloid extract and the weight proportion of solids in the psychoactive alkaloid extract are measured.
The psychoactive alkaloid content in the final composition is specified. A
measured amount of one or more excipients is added to the psychoactive alkaloid extract, such that, when the remaining solvent is evaporated, the resultant solid will have the specified content of psychoactive alkaloids. The specific amount of the total psychoactive alkaloid content in the standardized extract may be accurate to one or two decimal places, or one or two significant figures depending on how accurately the measurements are made during the mixing of the psychoactive alkaloid extract and the one or more excipients.
The excipients used in standardizing the extract may be, for example, one or more of the excipients that are in the final vaporizable composition, such as a fatty alcohol or an antioxidant.
1) or evaporation step 42 (FIG. 2), or it may be done after either of these steps.
Standardization is more conveniently done when the extract is a slurry than a powder, but it is not necessary that it is a slurry. Firstly, for example for a slurry, the weight percentage of the psychoactive alkaloids in the psychoactive alkaloid extract and the weight proportion of solids in the psychoactive alkaloid extract are measured.
The psychoactive alkaloid content in the final composition is specified. A
measured amount of one or more excipients is added to the psychoactive alkaloid extract, such that, when the remaining solvent is evaporated, the resultant solid will have the specified content of psychoactive alkaloids. The specific amount of the total psychoactive alkaloid content in the standardized extract may be accurate to one or two decimal places, or one or two significant figures depending on how accurately the measurements are made during the mixing of the psychoactive alkaloid extract and the one or more excipients.
The excipients used in standardizing the extract may be, for example, one or more of the excipients that are in the final vaporizable composition, such as a fatty alcohol or an antioxidant.
[0116] Standardization results in a standardized, extracted psychoactive alkaloid composition or a standardized psychoactive alkaloid extract. The standardized psychoactive alkaloid extract obtained has a specific amount of total psychoactive alkaloid content. Further, the psychoactive alkaloid is made up of a psychoactive alkaloid with a controlled amount of dephosphorylation, and possibly other psychoactive alkaloids that are not dephosphorylatable.
[0117] In other embodiments, the standardization process occurs at the time of preparation of the vaporizable composition, in FIG. 3. This is done by selecting the quantities of excipients and psychoactive component so that the final, vaporizable composition has the specified concentration of psychoactive alkaloids.
F. Preparation of composition
F. Preparation of composition
[0118] In some embodiments, referring to FIG. 3, the key steps of a process for forming a vaporizable psychoactive alkaloid composition are shown.
[0119] Step 44 involves mixing the carrier (i.e. alcohol, polyol, or both) with the purified psychoactive alkaloid extract and the antioxidant (if used) until the mixture is Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
homogenous. After this, the fatty acid and fatty alcohol are added to the mixture in step 46, and mixed until homogenous. The fatty acid and fatty alcohol may be added sequentially or together. This particular order of mixing helps with homogenization; if other mixing orders are used then layers might be formed. A person of skill in the art will appreciate that the mixing steps can be performed by any suitable methods, which do not cause any damage to the active pharmaceutical ingredients or the excipients, as known in the literature. Following this, in step 48, the flavoring agent (if used) is added to the mixture and mixed until homogenous.
PSU005c-PCT
homogenous. After this, the fatty acid and fatty alcohol are added to the mixture in step 46, and mixed until homogenous. The fatty acid and fatty alcohol may be added sequentially or together. This particular order of mixing helps with homogenization; if other mixing orders are used then layers might be formed. A person of skill in the art will appreciate that the mixing steps can be performed by any suitable methods, which do not cause any damage to the active pharmaceutical ingredients or the excipients, as known in the literature. Following this, in step 48, the flavoring agent (if used) is added to the mixture and mixed until homogenous.
[0120] Finally, the mixture is ready to be packaged and stored, in step 50. In some embodiments, the mixture is stored in glass jars or vials, between 4-30 C and in complete darkness.
G. Examples
G. Examples
[0121] In order to further illustrate the present invention, the following specific examples are given with the understanding that these examples are intended only to be illustrations without serving as a limitation on the scope of the present invention. All parameters, dimensions, materials, quantities and configurations described herein are examples only and may be changed depending on the specific embodiment. The process may be scaled up using larger quantities and modified apparatus.
[0122] Although the examples of the present invention have been formulated specifically using Psilocybe cubensis as a source to obtain a psychoactive alkaloid extract, the extract comprising predominantly dephosphorylated psychoactive alkaloid (e.g. psilocin), other sources are possible. A person skilled in the art would appreciate that the Psilocybe cubensis can be readily substituted by other sources of psychoactive alkaloids to obtain a variety of psychoactive alkaloids having similar properties, such psilocybin, baeocystin, norbaeocystin, aeruginascin, psilocin, norpsilocin, 4-hydroxytryptamine, N,N,N-trimethy1-4-hydroxytryptamine, or any combination therefrom, to name a few, to result in compositions with similar efficacy and efficiency as well. For example, mushrooms from the genus Conocybe, Copelandia, Galerina, Gymnopilus, Inocybe, Panaeolus, Pholiotina, Pluteus, Psilocybe, or any combination therefrom may be used.
Example 1: Extraction process with promotion of dephosphorylation Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
Example 1: Extraction process with promotion of dephosphorylation Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
[0123] 2.5 kilograms of Psilocybe cubensis were dried in a forced air oven at 25 C for hours to result in 140 grams of dried biomass. The dried biomass was then pulverized to a size of 200 mesh with a hammer mill.
[0124] An acidified solvent, i.e. a pH-adjusted, hydro-ethanol mixture, was prepared.
144 g of anhydrous citric acid was placed into a 5 L vessel with 1.25 L of reverse osmosis water, followed by the addition of 3.75 L of ethanol. The contents were mixed until completely dissolved. An acidified solvent with a pH of 2 was obtained.
144 g of anhydrous citric acid was placed into a 5 L vessel with 1.25 L of reverse osmosis water, followed by the addition of 3.75 L of ethanol. The contents were mixed until completely dissolved. An acidified solvent with a pH of 2 was obtained.
[0125] The dried powdered biomass was placed into an agitated, heat-controlled vessel with 5 L of the acidified solvent and mixed for the extraction of psychoactive alkaloid.
The extraction was controlled to a constant 75 C, and the duration of extraction was 1 hour. The extraction slurry was then filtered. Filtration resulted in a filtrate, i.e. the psychoactive alkaloid liquid, and a filter residue. The filter residue was placed back into the extraction vessel and extracted with an additional 5 L of the acidified solvent. The temperature of extraction was again 75 C and the time was 1 hour. The extraction slurry was filtered. The filtrates from the first and second extraction were mixed to form 10 L of mixed filtrate. The pH of the mixed filtrate was then increased with 5 M sodium hydroxide until a pH of 4.5 was achieved. Immediately after adjusting the pH, the mixed filtrate was placed into a rotary evaporator at 50 C and 250 torr, and the solvent was partially evaporated to obtain a psychoactive alkaloid extract. Final stages of evaporation were performed using a freeze dryer, and then the psychoactive alkaloid extract was obtained. When dried to a powder, the psychoactive alkaloid extract had a total psychoactive alkaloid concentration of 0.86% by weight of the psychoactive alkaloid extract. Further, the desired amount of the phosphorylated psychoactive alkaloid obtained was 0.00% by weight of the total psychoactive alkaloid content in the psychoactive alkaloid extract. The desired amount of the dephosphorylated psychoactive alkaloid obtained was 100% by weight of the total psychoactive alkaloid content in the psychoactive alkaloid extract.
Example 2.1: Purification with a non-ionic macroporous resin
The extraction was controlled to a constant 75 C, and the duration of extraction was 1 hour. The extraction slurry was then filtered. Filtration resulted in a filtrate, i.e. the psychoactive alkaloid liquid, and a filter residue. The filter residue was placed back into the extraction vessel and extracted with an additional 5 L of the acidified solvent. The temperature of extraction was again 75 C and the time was 1 hour. The extraction slurry was filtered. The filtrates from the first and second extraction were mixed to form 10 L of mixed filtrate. The pH of the mixed filtrate was then increased with 5 M sodium hydroxide until a pH of 4.5 was achieved. Immediately after adjusting the pH, the mixed filtrate was placed into a rotary evaporator at 50 C and 250 torr, and the solvent was partially evaporated to obtain a psychoactive alkaloid extract. Final stages of evaporation were performed using a freeze dryer, and then the psychoactive alkaloid extract was obtained. When dried to a powder, the psychoactive alkaloid extract had a total psychoactive alkaloid concentration of 0.86% by weight of the psychoactive alkaloid extract. Further, the desired amount of the phosphorylated psychoactive alkaloid obtained was 0.00% by weight of the total psychoactive alkaloid content in the psychoactive alkaloid extract. The desired amount of the dephosphorylated psychoactive alkaloid obtained was 100% by weight of the total psychoactive alkaloid content in the psychoactive alkaloid extract.
Example 2.1: Purification with a non-ionic macroporous resin
[0126] The pH of the psychoactive alkaloid extract of example 1, in aqueous form, was adjusted to pH 4.0 (+1- 0.5) by adding 2 M phosphoric acid and centrifuged for minutes at 3000g to remove any solid precipitate. The pH of 4 corresponds to the isoelectric point of psilocybin, and psilocin's polarity is such that it is partitioned onto the resin, thus allowing effective binding of the psychoactive alkaloids psilocybin (if present, Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
i.e. dephosphorylation is not used or is incomplete) and psilocin to the macroporous resin. Norbaeocystin and baeocystin are phosphorylated and if present would behave in the same way as psilocybin. The supernatant obtained was loaded onto a column of Amberlite XAD4, a non-ionic macroporous resin (50.34 g of dry resin) at a flow rate of 2 bed volumes per hour, to allow components in the supernatant to be adsorbed onto the macroporous resin. After all 2.5 L of the extract was loaded onto the column of macroporous resin, the column was washed in a single pass with 5 bed volumes of reverse osmosis water at room temperature. This was followed by elution with 5 bed volumes of 5% ethanol (by weight), again at room temperature. Finally, the column was washed in a single pass with 5 bed volumes of 100% ethanol. The elution was performed at room temperature. Each of these three fractions was collected separately.
The particular order for the washing steps and the elution was selected to be in the order of the polarity of the solvents. If the order were different, an inferior result may have ensued, such as a lower yield. The first fraction using reverse osmosis water removed the most polar compounds from the resin. The hydroethanol fraction eluted compounds of lesser polarity, and the 100% ethanol solvent removed the least polar compounds. Less polar solvents could also be used to elute less polar compounds.
PSU005c-PCT
i.e. dephosphorylation is not used or is incomplete) and psilocin to the macroporous resin. Norbaeocystin and baeocystin are phosphorylated and if present would behave in the same way as psilocybin. The supernatant obtained was loaded onto a column of Amberlite XAD4, a non-ionic macroporous resin (50.34 g of dry resin) at a flow rate of 2 bed volumes per hour, to allow components in the supernatant to be adsorbed onto the macroporous resin. After all 2.5 L of the extract was loaded onto the column of macroporous resin, the column was washed in a single pass with 5 bed volumes of reverse osmosis water at room temperature. This was followed by elution with 5 bed volumes of 5% ethanol (by weight), again at room temperature. Finally, the column was washed in a single pass with 5 bed volumes of 100% ethanol. The elution was performed at room temperature. Each of these three fractions was collected separately.
The particular order for the washing steps and the elution was selected to be in the order of the polarity of the solvents. If the order were different, an inferior result may have ensued, such as a lower yield. The first fraction using reverse osmosis water removed the most polar compounds from the resin. The hydroethanol fraction eluted compounds of lesser polarity, and the 100% ethanol solvent removed the least polar compounds. Less polar solvents could also be used to elute less polar compounds.
[0127] The 5% ethanol fraction (i.e. the purified psychoactive alkaloid solution) was then concentrated in a rotary evaporator to form 3.90 g of concentrated aqueous slurry at 30% solids, containing 195.1 mg of total alkaloids (e.g. psilocin and possibly other dephosphorylated psychoactive alkaloids). The result was a purified psychoactive alkaloid extract, in slurry form. Further, the desired amount of the psychoactive alkaloid obtained was 5.00% by weight of the slurry. Knowing this, it is possible to replace the solvent with an equivalent weight of excipients to provide a purified extract with a psychoactive alkaloid content of 5.00% dry weight. A greater or lesser amount of excipients will result, respectively, in a lower or higher psychoactive alkaloid content.
[0128] A similar process may be used for purification of extracts that have been obtained without the dephosphorylation control.
Example 2.2: Purification with cation exchange and non-ionic macroporous resins
Example 2.2: Purification with cation exchange and non-ionic macroporous resins
[0129] The pH of the psychoactive alkaloid extract of example 1, in aqueous form, was adjusted to a pH of 3.0 (+1- 0.5) by adding 1M HCI. It was then mixed with 200 g of Amberlite MAC-3 H, a strong cationic ion-exchange resin in its hydrogen form, to result in a filtrate-resin mixture, in which components of the psychoactive alkaloid filtrate were Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
adsorbed onto the cation exchange resin. Psilocin's polarity is such that it is partitioned onto the resin. The pH of 3 would also ensure that psilocybin, if present, was in its protonated form, and thus also adsorbed onto the cationic exchange resin efficiently.
The filtrate-resin mixture was agitated for 4 hours at room temperature (21 C
¨ 25 C) and then filtered. The filtrate was discarded, and the resin was rinsed with 2.0 L of 100% Et0H and then 2.0 L of H20 to remove any impurities. Finally, the psilocin (and, in other cases, psilocybin) fraction was eluted with 2.0 L of 2% HC1/80 /0 Et0H, for 4 hours at room temperature.
PSU005c-PCT
adsorbed onto the cation exchange resin. Psilocin's polarity is such that it is partitioned onto the resin. The pH of 3 would also ensure that psilocybin, if present, was in its protonated form, and thus also adsorbed onto the cationic exchange resin efficiently.
The filtrate-resin mixture was agitated for 4 hours at room temperature (21 C
¨ 25 C) and then filtered. The filtrate was discarded, and the resin was rinsed with 2.0 L of 100% Et0H and then 2.0 L of H20 to remove any impurities. Finally, the psilocin (and, in other cases, psilocybin) fraction was eluted with 2.0 L of 2% HC1/80 /0 Et0H, for 4 hours at room temperature.
[0130] The eluted fraction was brought to a pH of 4.0 (i.e. the isoelectric point of psilocybin) by adding 2M NaOH. The filtrate was then centrifuged at 3000g to remove any solid precipitate. The resultant filtrate, in form of an aqueous solution, was then placed into a rotary evaporator and the solvent was removed until the aqueous solution reached a volume of 400 mL. The aqueous solution was then again centrifuged for 15 minutes at 3000g to remove any solid precipitate. The supernatant was loaded onto a column of Amberlite XAD4 macroporous resin (45.53 g of dry resin) at a flow rate of 2 bed volumes per hour. After all the 400 mL of the supernatant was loaded onto the column, it was initially washed with 5 bed volumes of reverse osmosis water, followed by elution with 5 bed volumes of 5% ethanol (by weight) and then washed with 100%
ethanol. Each of these fractions was collected separately. The 5% ethanol fraction (i.e.
the purified psychoactive alkaloid solution) was concentrated in a rotary evaporator to form 258 mg of solution containing 175 mg of total psychoactive alkaloids (i.e. psilocin and other dephosphorylated psychoactive alkaloids). Thus, a purified psychoactive alkaloid extract, in slurry form, with a total alkaloid concentration of 68%
dry wt/wt% was obtained.
ethanol. Each of these fractions was collected separately. The 5% ethanol fraction (i.e.
the purified psychoactive alkaloid solution) was concentrated in a rotary evaporator to form 258 mg of solution containing 175 mg of total psychoactive alkaloids (i.e. psilocin and other dephosphorylated psychoactive alkaloids). Thus, a purified psychoactive alkaloid extract, in slurry form, with a total alkaloid concentration of 68%
dry wt/wt% was obtained.
[0131] A similar process may be used for purification of extracts that have been obtained without the dephosphorylation control.
Example 2.3: Purification with anion exchange and non-ionic macroporous resins
Example 2.3: Purification with anion exchange and non-ionic macroporous resins
[0132] The pH of the psychoactive alkaloid extract of example 1, which was in aqueous form, was adjusted to 9.5 (+1- 0.5) by adding 1 M NaOH and then mixed with 150g of Amberchrom 50WX8 strong anionic ion-exchange resin in its hydrogen form to result in a filtrate-resin mixture, in which components of the psychoactive alkaloid filtrate were adsorbed onto the anion exchange resin. The pH of 9.5 (+1- 0.5) ensured that the Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
psychoactive alkaloids (e.g. psilocin) were deprotonated and had a net negative charge for efficient adsorption onto the strong anion exchanger.
PSU005c-PCT
psychoactive alkaloids (e.g. psilocin) were deprotonated and had a net negative charge for efficient adsorption onto the strong anion exchanger.
[0133] The filtrate-resin mixture was agitated for 4 hours and then filtered out, and the filtrate was discarded. The resin was rinsed with 2.0 L of 100% Et0H and then 2.0 L of H20 to remove impurities. Finally, the psychoactive alkaloid fraction was eluted with 2.0 L of 2% NaCl/80 /0 Et0H for 4 hours.
[0134] The eluted fraction was brought to a pH of 4.0 with the addition 2 M
HCI. The extract was then centrifuged at 3000g to remove any solid precipitate. The resultant extract, in from of a solution, was then placed into a rotary evaporator and the solvent was removed to result in a volume of 400 mL.
HCI. The extract was then centrifuged at 3000g to remove any solid precipitate. The resultant extract, in from of a solution, was then placed into a rotary evaporator and the solvent was removed to result in a volume of 400 mL.
[0135] The resultant 400 mL aqueous solution was centrifuged for 15 minutes at 3000g to remove any solid precipitate. The supernatant was loaded onto a column of Amberlite XAD4 macroporous resin (45.53 g of dry resin) at a flow rate of 2 bed volumes per hour, to allow components of the supernatant to be adsorbed onto the macroporous resin. After all 400 mL of supernatant was loaded onto the column, the column was initially washed with 5 bed volumes of reverse osmosis water, followed by elution with 5 bed volumes of 5% ethanol (by weight) and then a final wash with 100%
ethanol was performed. Each of these fractions was collected separately. The 5%
ethanol fraction (i.e. the purified psychoactive alkaloid solution) was concentrated in a rotary evaporator to form 325 mg of solution containing 175 mg of total alkaloids (e.g.
psilocin and other dephosphorylated psychoactive alkaloids). A purified psychoactive alkaloid extract, in slurry form, with a concentration of 54% dry wt/wt% of total alkaloids was therefore obtained.
ethanol was performed. Each of these fractions was collected separately. The 5%
ethanol fraction (i.e. the purified psychoactive alkaloid solution) was concentrated in a rotary evaporator to form 325 mg of solution containing 175 mg of total alkaloids (e.g.
psilocin and other dephosphorylated psychoactive alkaloids). A purified psychoactive alkaloid extract, in slurry form, with a concentration of 54% dry wt/wt% of total alkaloids was therefore obtained.
[0136] A similar process may be used for purification of extracts that have been obtained without the dephosphorylation control.
Example 3.1: First vaporizable composition
Example 3.1: First vaporizable composition
[0137] In this example, shown in TABLE 2, the psychoactive component is a 10%
extract, i.e. a purified, standardized extract in the powder form that has a psychoactive alkaloid concentration of 10% by weight. In particular, the phosphorylatable alkaloids in the extract were dephosphorylated during extraction. The total psychoactive alkaloid content in the 10 mg amount of extract used was 1.0 mg.
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22:57:18 CET
PSU005c-PCT
Component Specific % g added Ingredient Psychoactive 10% extract 2 0.010 component Carrier Propylene glycol 65 0.325 Fatty acid Oleic acid 20 0.100 Fatty alcohol 2-Ethyl hexanol 10 0.050 Antioxidant Alpha tocopherol 1 0.005 Flavoring menthol 2 0.010 Total = Total =
100 0.500 Example 3.2: Second vaporizable composition
extract, i.e. a purified, standardized extract in the powder form that has a psychoactive alkaloid concentration of 10% by weight. In particular, the phosphorylatable alkaloids in the extract were dephosphorylated during extraction. The total psychoactive alkaloid content in the 10 mg amount of extract used was 1.0 mg.
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22:57:18 CET
PSU005c-PCT
Component Specific % g added Ingredient Psychoactive 10% extract 2 0.010 component Carrier Propylene glycol 65 0.325 Fatty acid Oleic acid 20 0.100 Fatty alcohol 2-Ethyl hexanol 10 0.050 Antioxidant Alpha tocopherol 1 0.005 Flavoring menthol 2 0.010 Total = Total =
100 0.500 Example 3.2: Second vaporizable composition
[0138] In this example, shown in TABLE 3, the psychoactive component is a 30%
extract, i.e. a purified, powdered extract that has a psychoactive alkaloid concentration of 30% by weight. In particular, the phosphorylatable alkaloids in the extract were dephosphorylated during extraction. The total psychoactive alkaloid content in the composition is 1.02 mg.
Component Specific % g added Ingredient Psychoactive 30% extract 0.68 0.0034 component Carrier Ethanol 15 0.075 Fatty acid Linolenic acid 62 0.310 Fatty alcohol Cetyl alcohol 20 0.100 Antioxidant Ascorbic acid 1 0.005 Flavoring menthol 1.32 0.0066 Total Total =
= 100 0.500 H. Apparatus
extract, i.e. a purified, powdered extract that has a psychoactive alkaloid concentration of 30% by weight. In particular, the phosphorylatable alkaloids in the extract were dephosphorylated during extraction. The total psychoactive alkaloid content in the composition is 1.02 mg.
Component Specific % g added Ingredient Psychoactive 30% extract 0.68 0.0034 component Carrier Ethanol 15 0.075 Fatty acid Linolenic acid 62 0.310 Fatty alcohol Cetyl alcohol 20 0.100 Antioxidant Ascorbic acid 1 0.005 Flavoring menthol 1.32 0.0066 Total Total =
= 100 0.500 H. Apparatus
[0139] FIG. 4 depicts an apparatus used for obtaining a psychoactive alkaloid extract and forming a vaporizable composition. In one example, raw Psilocybe cubensis mushrooms are added to a hopper 100 and then released in batches into container 102.
The raw fungal material is then dried in a forced air oven 104 to result in the dried Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
biomass. The dried biomass is placed into a grinder 106 for grinding to result in dried powdered biomass.
The raw fungal material is then dried in a forced air oven 104 to result in the dried Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
biomass. The dried biomass is placed into a grinder 106 for grinding to result in dried powdered biomass.
[0140] The dried powdered biomass is then placed into a heat-controlled vessel and acidified solvent (S) added to the heat-controlled vessel to obtain a specific pH (e.g.
lower than 3.5). The vessel 110 is surrounded by an insulating wall 108.
Alternately, an insulating jacket may be wrapped around the vessel. The insulating wall 108 or jacket helps to maintain the contents 112 under a constant temperature (T) between 5 ¨ 95 C.
The applied pressure (P) inside the extraction vessel 110 may be regulated from 50kPa to 140MPa (7 to 20,000 psi). The extraction may be performed with a solvent to solid (dried powdered biomass) proportion in the range of 1L:1kg to 50L:1kg.
lower than 3.5). The vessel 110 is surrounded by an insulating wall 108.
Alternately, an insulating jacket may be wrapped around the vessel. The insulating wall 108 or jacket helps to maintain the contents 112 under a constant temperature (T) between 5 ¨ 95 C.
The applied pressure (P) inside the extraction vessel 110 may be regulated from 50kPa to 140MPa (7 to 20,000 psi). The extraction may be performed with a solvent to solid (dried powdered biomass) proportion in the range of 1L:1kg to 50L:1kg.
[0141] After the extraction, the bottom of the extraction vessel 110 may be opened at outlet 114 and the extraction slurry collected in a container 120. The extraction slurry is then fed into a filter 122 and a first filtrate collected in container 124.
The first filtrate residue 130 may then be fed back (R) into the agitated, heat-controlled vessel 110 and more solvent (S) added for a second extraction. After the second extraction, the extraction slurry may be collected in the container 120 and then fed into a filter 132.
After filtration, the obtained second filtrate is collected in container 136.
The first filtrate residue 130 may then be fed back (R) into the agitated, heat-controlled vessel 110 and more solvent (S) added for a second extraction. After the second extraction, the extraction slurry may be collected in the container 120 and then fed into a filter 132.
After filtration, the obtained second filtrate is collected in container 136.
[0142] After the two filtration stages, the filtrates are mixed in container 140 to obtain a mixed filtrate i.e. the psychoactive alkaloid liquid. In other embodiments, if there is only a single filtration step, this mixing step is not required. By adding a base to container 140, the pH of the psychoactive alkaloid liquid may be brought to a pH ranging from 3.5-4.5.
[0143] The pH-adjusted, mixed filtrate is then placed in a rotary evaporator 142 and part of the solvent evaporated from the mixed filtrate to form the psychoactive alkaloid extract, which is here a slurry.
[0144] The resultant slurry is then transferred to a container 144 where a measured quantity of one or more excipients is added to obtain a standardized psychoactive alkaloid composition in slurry form. The obtained standardized slurry may then be then dried to obtain the standardized psychoactive alkaloid composition.
[0145] In another example, a purified, standardized psychoactive composition may be obtained. The resultant slurry from the rotary evaporator 142 is transferred to the container 144, where the pH of the extract may be adjusted, followed by centrifugation
146 to remove the solid precipitates.
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
[0146] The resultant supernatant is loaded onto a column 150 of resin. An initial wash is given to the column with a solvent to remove impurities from the resin, and fraction 154 is collected. A second wash is given to the column with another solvent to elute the psychoactive alkaloids from the column and result in fraction 156. A final wash is given to the column with another solvent to wash any impurities from the column, to prepare the column for use again, and the fraction 158 is obtained. The elution fraction 156 with the psychoactive alkaloids is then concentrated in a rotary evaporator 160 to result in the purified psychoactive alkaloid solution. The solvent from the purified psychoactive alkaloid solution is then completely or partially evaporated to result in the purified psychoactive alkaloid extract 164. This extract may then be standardized by adding a measured amount of excipient to it and mixing, in container 166. If necessary, the mixture may then be dried.
Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
[0146] The resultant supernatant is loaded onto a column 150 of resin. An initial wash is given to the column with a solvent to remove impurities from the resin, and fraction 154 is collected. A second wash is given to the column with another solvent to elute the psychoactive alkaloids from the column and result in fraction 156. A final wash is given to the column with another solvent to wash any impurities from the column, to prepare the column for use again, and the fraction 158 is obtained. The elution fraction 156 with the psychoactive alkaloids is then concentrated in a rotary evaporator 160 to result in the purified psychoactive alkaloid solution. The solvent from the purified psychoactive alkaloid solution is then completely or partially evaporated to result in the purified psychoactive alkaloid extract 164. This extract may then be standardized by adding a measured amount of excipient to it and mixing, in container 166. If necessary, the mixture may then be dried.
[0147] The standardized, purified psychoactive composition 166 or the standardized psychoactive composition obtained in container 144 may then be mixed with an alcohol carrier and other excipients in container 166 or 144 to form the psychoactive vaporizable composition. The vaporizable psychoactive composition may then be stored in a vial 168, for example.
[0148] In other examples, parts of the apparatus may be reused or duplicated.
For example, if desired, the elution fraction 156 may be reloaded into the container 144 for pH adjustment and the steps from thereon can be repeated to allow for further purification of the obtained purified psychoactive alkaloid solution.
I. Conclusion
For example, if desired, the elution fraction 156 may be reloaded into the container 144 for pH adjustment and the steps from thereon can be repeated to allow for further purification of the obtained purified psychoactive alkaloid solution.
I. Conclusion
[0149] Throughout the description, specific details have been set forth in order to provide a more thorough understanding of the invention. However, the invention may be practiced without these particulars. In other instances, well known elements have not been shown or described in detail and repetitions of steps and features have been omitted to avoid unnecessarily obscuring the invention. Accordingly, the specification and drawings are to be regarded in an illustrative, rather than a restrictive, sense.
[0150] It will be clear to one having skill in the art that further variations to the specific details disclosed herein can be made, resulting in other embodiments that are within the scope of the invention disclosed. Steps in the flowchart may be performed in a different order, other steps may be added, or one or more may be removed without altering the main outcome of the processes. In some embodiments, the extract may be replaced Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22 57 18 CET
PSU005c-PCT
with a synthetic psychoactive alkaloid source or composition. The process may be scaled up using larger quantities and a modified apparatus.
PSU005c-PCT
with a synthetic psychoactive alkaloid source or composition. The process may be scaled up using larger quantities and a modified apparatus.
[0151] All parameters, dimensions, materials, quantities and configurations described herein are examples only and may be changed depending on the specific embodiment.
Numbers are given to the nearest significant figure, or to 10%, whichever is the greater.
Temperatures that have been given to the nearest degree include all temperatures within a range of 0.5 C of the given value. Integer values of pH are understood to be specified to 0.5 or, when expressed as a decimal, to the nearest significant digit, unless specifically indicated otherwise.
Numbers are given to the nearest significant figure, or to 10%, whichever is the greater.
Temperatures that have been given to the nearest degree include all temperatures within a range of 0.5 C of the given value. Integer values of pH are understood to be specified to 0.5 or, when expressed as a decimal, to the nearest significant digit, unless specifically indicated otherwise.
[0152] Any of the solvents described herein may be used with any of the organisms that have psychoactive alkaloids.
[0153] As will be understood by one skilled in the art, for any and all purposes, such as in terms of providing a written description, all ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. For example, if a range is given as m-q, then the ranges m-n, n-p and p-q are included each as a separate embodiment, where n and p are any values that satisfy m<n<p<q.
[0154] In some embodiments, as the ranges become narrower and more central compared to the greatest range, the properties of the embodiments generally become more balanced, such properties being solubility, viscosity, flowability, stability, potency, immediate potency, delayed potency, cost of production, efficiency of production, production time, compatibility of the psychoactive alkaloid composition, psychoactive efficacy of the psychoactive alkaloid extract, psychoactive efficacy of the psychoactive alkaloid composition, vaporability and so on. As the ranges become narrower towards one extreme or other of the widest range, a particular property of the composition or process generally becomes more pronounced relative to the other properties.
The specific range is to be chosen depending on how the properties are to be traded off against each other. As will also be understood by one skilled in the art, all language such as "up to," and the like include the number recited, and any tolerance explicitly or implicitly associated with it, and refer to ranges which can be subsequently broken Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22:57:18 CET
PSU005c-PCT
down into subranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member.
The specific range is to be chosen depending on how the properties are to be traded off against each other. As will also be understood by one skilled in the art, all language such as "up to," and the like include the number recited, and any tolerance explicitly or implicitly associated with it, and refer to ranges which can be subsequently broken Date Recue/Date Received 2022-06-03 Rendered by ePCT style sheet on 22 Dec 2021 at 22:57:18 CET
PSU005c-PCT
down into subranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member.
[0155] Accordingly, the scope of the invention is to be construed in accordance with the substance defined by the claims.
Date Recue/Date Received 2022-06-03
Date Recue/Date Received 2022-06-03
Claims (31)
1. A liquid, vaporizable psychoactive alkaloid composition made by mixing, by weight:
0.1-15% of a psychoactive alkaloid component;
5-71.9% of alcohol, polyol, or an alcohol and polyol mixture;
2-78.1% of fatty acid;
5-40% of fatty alcohol;
0-10% of antioxidant; and 0-10% of flavorant.
0.1-15% of a psychoactive alkaloid component;
5-71.9% of alcohol, polyol, or an alcohol and polyol mixture;
2-78.1% of fatty acid;
5-40% of fatty alcohol;
0-10% of antioxidant; and 0-10% of flavorant.
2. The composition of claim 1, wherein the psychoactive alkaloid component comprises more dephosphorylated psychoactive alkaloid than phosphorylated psychoactive alkaloid.
3. The composition of claim 2, wherein:
the phosphorylated psychoactive alkaloid is psi locybi n, baeocystin, norbaeocystin, aeruginascin, or any combination selected therefrom; and the dephosphorylated psychoactive alkaloid is psilocin, bufotenine, bufotenidine, norpsilocin, 4-hyd roxytryptam i ne, N,N,N-trimethyl-4-hydroxytryptamine, or any combination selected therefrom.
the phosphorylated psychoactive alkaloid is psi locybi n, baeocystin, norbaeocystin, aeruginascin, or any combination selected therefrom; and the dephosphorylated psychoactive alkaloid is psilocin, bufotenine, bufotenidine, norpsilocin, 4-hyd roxytryptam i ne, N,N,N-trimethyl-4-hydroxytryptamine, or any combination selected therefrom.
4. The composition of claim 1, wherein the psychoactive alkaloid component comprises phosphorylatable psychoactive alkaloid that is 100%
dephosphorylated.
dephosphorylated.
5. The composition of claim 1, comprising 6-10% of the psychoactive alkaloid component, wherein the psychoactive alkaloid component is an extract.
6. The composition of claim 1, wherein the psychoactive alkaloid component is an extract that has a total psychoactive alkaloid content ranging from 0.1% to 99% by weight.
Date Recue/Date Received 2022-10-03 PSU005c-CANE
Date Recue/Date Received 2022-10-03 PSU005c-CANE
7. The composition of claim 6, wherein the extract is a purified extract, and the purified extract has a total psychoactive alkaloid content ranging from 10% to 99% by weight.
8. The composition of claim 6, wherein the extract comprises naturally occurring substances from the group consisting of fats, sugars, carbohydrates, chitin, chitosan, minerals, waxes, proteins and any combination selected therefrom, and the naturally occurring substances are present in the extract in a concentration ranging from 1% to 99.9% by weight.
9. The composition of claim 1, wherein the psychoactive alkaloid component is synthetic.
10. The composition of claim 1, made using 50-70% by weight of the alcohol, polyol, or alcohol and polyol mixture.
11. The composition of claim 1, wherein the alcohol, polyol, or alcohol and polyol mixture is ethanol, 1-propanol, isopropyl alcohol, tert-butyl alcohol, glycerine, polyethylene glycol, propylene glycol or any combination selected therefrom.
12. The composition of claim 1, made using 20% by weight of the fatty acid.
13. The composition of claim 1, wherein the fatty acid is palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, ascorbyl palmitate, cetyl palmitate, colfosceril palmitate, ehtylhexyl palmitate, isopropyl palmitate, palmitoyl-CoA, retinyl palmitate, sucrose monopalmitate or any combination selected therefrom.
14. The composition of claim 1, made using 8-12% by weight of the fatty alcohol.
15. The composition of claim 1, wherein the fatty alcohol is capryl alcohol (1-octanol), 2-ethyl hexanol, pelargonic alcohol (1-nonanol), capric alcohol (1-decanol, decyl alcohol), undecyl alcohol (1-undecanol, undecanol, hendecanol), lauryl alcohol (dodecanol, 1-dodecanol), tridecyl alcohol (1-tridecanol, tridecanol, isotridecanol), Date Recue/Date Received 2022-10-03 PSU005c-CANE
myristyl alcohol (1-tetradecanol), pentadecyl alcohol (1-pentadecanol, pentadecanol), cetyl alcohol (1-hexadecanol), palmitoleyl alcohol (cis-9-hexadecen-1-ol), heptadecyl alcohol (1-n-heptadecanol, heptadecanol), stearyl alcohol (1-octadecanol), isostearyl alcohol (16-methylheptadecan-1-01), elaidyl alcohol (9E-octadecen-1-ol), oleyl alcohol (cis-9-octadecen-1-ol), linoleyl alcohol (9Z,12Z-octadecadien-1-ol), elaidolinoleyl alcohol (9E,12E-octadecadien-1-ol), linolenyl alcohol (9Z,12Z,15Z-octadecatrien-1-ol), elaidolinolenyl alcohol (9E,12E,15-E-octadecatrien-1-ol), ricinoleyl alcohol (12-hydroxy-9-octadecen-1-ol), nonadecyl alcohol (1-nonadecanol), arachidyl alcohol (1-eicosanol), heneicosyl alcohol (1-heneicosanol), behenyl alcohol (1-docosanol), erucyl alcohol (cis-13-docosen-1-ol), lignoceryl alcohol (1-tetracosanol), ceryl alcohol (1-hexacosanol), 1-heptacosanol, montanyl alcohol, cluytyl alcohol (1-octacosanol), 1-nonacosanol, myricyl alcohol, melissyl alcohol (1-triacontanol), 1-dotriacontanol, geddyl alcohol (1-tetratriacontanol) or any combination selected therefrom.
myristyl alcohol (1-tetradecanol), pentadecyl alcohol (1-pentadecanol, pentadecanol), cetyl alcohol (1-hexadecanol), palmitoleyl alcohol (cis-9-hexadecen-1-ol), heptadecyl alcohol (1-n-heptadecanol, heptadecanol), stearyl alcohol (1-octadecanol), isostearyl alcohol (16-methylheptadecan-1-01), elaidyl alcohol (9E-octadecen-1-ol), oleyl alcohol (cis-9-octadecen-1-ol), linoleyl alcohol (9Z,12Z-octadecadien-1-ol), elaidolinoleyl alcohol (9E,12E-octadecadien-1-ol), linolenyl alcohol (9Z,12Z,15Z-octadecatrien-1-ol), elaidolinolenyl alcohol (9E,12E,15-E-octadecatrien-1-ol), ricinoleyl alcohol (12-hydroxy-9-octadecen-1-ol), nonadecyl alcohol (1-nonadecanol), arachidyl alcohol (1-eicosanol), heneicosyl alcohol (1-heneicosanol), behenyl alcohol (1-docosanol), erucyl alcohol (cis-13-docosen-1-ol), lignoceryl alcohol (1-tetracosanol), ceryl alcohol (1-hexacosanol), 1-heptacosanol, montanyl alcohol, cluytyl alcohol (1-octacosanol), 1-nonacosanol, myricyl alcohol, melissyl alcohol (1-triacontanol), 1-dotriacontanol, geddyl alcohol (1-tetratriacontanol) or any combination selected therefrom.
16. The composition of claim 1, wherein the antioxidant is citric acid, butylated hydroxytoluene, ascorbic acid, glutathione, retinol, a-tocopherol, 13-carotene, a-carotene, ubiquinone, butylated hydroxyanisole, ethylenediaminetetraacetic acid, selenium, zinc, lignan, uric acid, lipoic acid, N-acetylcysteine, ascorbic acid or any combination selected therefrom.
17. The composition of claim 1, wherein the flavorant is menthol, a sweetener or both menthol and a sweetener.
18. The composition of claim 1, further comprising up to 5% of one or more bioavailability enhancers.
19. The composition of claim 1, further comprising 0.5-2% of one or more bioavailability enhancers.
20. The composition of claim 1, wherein a total psychoactive alkaloid content in the composition is defined as a percentage to two decimal places.
Date Recue/Date Received 2022-10-03 PSU005c-CANE
Date Recue/Date Received 2022-10-03 PSU005c-CANE
21. The composition of claim 1, wherein at least some of the fatty acid reacts with at least some of the alcohol, polyol or alcohol and polyol to form fatty acid ester in the composition.
22. The composition of claim 1, wherein the psychoactive component has a pH
of 8.47 0.25.
of 8.47 0.25.
23. The composition of claim 1, having a pH in a range of 4-10.
24. A process for obtaining a liquid, vaporizable psychoactive alkaloid composition, the process comprising:
extracting psychoactive alkaloid from a dried powdered psychoactive alkaloid source, using an acidified solvent with a pH of 3.5 or lower, to obtain a psychoactive alkaloid liquid;
adjusting the pH of the psychoactive alkaloid liquid to a pH ranging from 3.5-4.5;
evaporating the acidified solvent from the psychoactive alkaloid liquid to obtain a psychoactive alkaloid extract; and mixing, by weight:
0.1-15% of the psychoactive alkaloid extract;
5-71.9% of alcohol, polyol, or an alcohol and polyol mixture;
2-78.1% of fatty acid;
5-40% of fatty alcohol;
0-10% of antioxidant; and 0-10% of flavorant;
to form the liquid, vaporizable psychoactive alkaloid composition.
extracting psychoactive alkaloid from a dried powdered psychoactive alkaloid source, using an acidified solvent with a pH of 3.5 or lower, to obtain a psychoactive alkaloid liquid;
adjusting the pH of the psychoactive alkaloid liquid to a pH ranging from 3.5-4.5;
evaporating the acidified solvent from the psychoactive alkaloid liquid to obtain a psychoactive alkaloid extract; and mixing, by weight:
0.1-15% of the psychoactive alkaloid extract;
5-71.9% of alcohol, polyol, or an alcohol and polyol mixture;
2-78.1% of fatty acid;
5-40% of fatty alcohol;
0-10% of antioxidant; and 0-10% of flavorant;
to form the liquid, vaporizable psychoactive alkaloid composition.
25. The process of claim 24, wherein:
the fatty acid and fatty alcohol are added to a homogenous mixture of the psychoactive alkaloid extract, antioxidant, and alcohol, polyol, or alcohol and polyol mixture; and the flavorant is added after addition of the fatty acid and fatty alcohol.
the fatty acid and fatty alcohol are added to a homogenous mixture of the psychoactive alkaloid extract, antioxidant, and alcohol, polyol, or alcohol and polyol mixture; and the flavorant is added after addition of the fatty acid and fatty alcohol.
26. The process of claim 24, wherein the acidified solvent has a pH ranging from 0.5-3.5.
Date Recue/Date Received 2022-10-03 PSU005c-CANE
Date Recue/Date Received 2022-10-03 PSU005c-CANE
27. The process of claim 24, wherein the extracting step comprises:
mixing the dried powdered psychoactive alkaloid source with the acidified solvent to obtain a slurry; and filtering the slurry to obtain a filtrate residue and the psychoactive alkaloid liquid.
mixing the dried powdered psychoactive alkaloid source with the acidified solvent to obtain a slurry; and filtering the slurry to obtain a filtrate residue and the psychoactive alkaloid liquid.
28. The process of claim 24, wherein the psychoactive alkaloid component comprises phosphorylatable psychoactive alkaloid that is 100%
dephosphorylated.
dephosphorylated.
29. The process of claim 24, further comprising purifying the psychoactive alkaloid extract prior to the mixing step by:
contacting the psychoactive alkaloid extract with a resinous material to obtain an adsorbed psychoactive alkaloid;
eluting the adsorbed psychoactive alkaloid using a solvent to obtain a purified psychoactive alkaloid solution, wherein the solvent is water, an organic solvent or a combination thereof, under basic, acidic or neutral pH; and evaporating the solvent to obtain a purified form of the psychoactive alkaloid extract.
contacting the psychoactive alkaloid extract with a resinous material to obtain an adsorbed psychoactive alkaloid;
eluting the adsorbed psychoactive alkaloid using a solvent to obtain a purified psychoactive alkaloid solution, wherein the solvent is water, an organic solvent or a combination thereof, under basic, acidic or neutral pH; and evaporating the solvent to obtain a purified form of the psychoactive alkaloid extract.
30. The process of claim 24, further comprising:
interrupting the evaporation step to result in a concentrated slurry;
measuring a psychoactive alkaloid content in the concentrated slurry;
measuring a dry mass content in the concentrated slurry;
using the psychoactive alkaloid content, the dry mass content and a specified concentration for the psychoactive alkaloid in the psychoactive alkaloid extract to determine a quantity of excipient to add to the concentrated slurry in order to obtain the specified concentration of the psychoactive alkaloid in the psychoactive alkaloid extract;
adding the excipient to the psychoactive alkaloid extract to standardize the psychoactive alkaloid extract; and continuing the evaporation step.
interrupting the evaporation step to result in a concentrated slurry;
measuring a psychoactive alkaloid content in the concentrated slurry;
measuring a dry mass content in the concentrated slurry;
using the psychoactive alkaloid content, the dry mass content and a specified concentration for the psychoactive alkaloid in the psychoactive alkaloid extract to determine a quantity of excipient to add to the concentrated slurry in order to obtain the specified concentration of the psychoactive alkaloid in the psychoactive alkaloid extract;
adding the excipient to the psychoactive alkaloid extract to standardize the psychoactive alkaloid extract; and continuing the evaporation step.
31. The process of claim 24, further comprising adding a bioavailability agent to the liquid, vaporizable psychoactive alkaloid composition.
Date Recue/Date Received 2022-10-03
Date Recue/Date Received 2022-10-03
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163139453P | 2021-01-20 | 2021-01-20 | |
US63/139,453 | 2021-01-20 | ||
PCT/CA2021/051876 WO2022140846A1 (en) | 2020-12-28 | 2021-12-22 | Vaporizable psychoactive alkaloid composition and preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CA3161491A1 CA3161491A1 (en) | 2022-07-20 |
CA3161491C true CA3161491C (en) | 2023-07-25 |
Family
ID=82482526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3161491A Active CA3161491C (en) | 2021-01-20 | 2021-12-22 | Vaporizable psychoactive alkaloid composition and preparation thereof |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA3161491C (en) |
-
2021
- 2021-12-22 CA CA3161491A patent/CA3161491C/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA3161491A1 (en) | 2022-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220313713A1 (en) | Vaporizable psychoactive alkaloid composition and preparation thereof | |
US11642385B2 (en) | Basic extraction of psychoactive compounds from psychoactive organisms | |
CA3097246C (en) | Process for obtaining a purified psychoactive alkaloid solution | |
US20210393717A1 (en) | Methods and compositions comprising psychoactive compounds from psychoactive organisms | |
WO2021253116A1 (en) | Compositions comprising psychoactive compounds from psychoactive organisms | |
CA3161491C (en) | Vaporizable psychoactive alkaloid composition and preparation thereof | |
CA3103707C (en) | Standardized psychoactive alkaloid extract composition | |
CA3137016C (en) | Psychoactive alkaloid extraction and composition with inhibited dephosphorylation | |
US11510952B2 (en) | Ethanol extraction of psychoactive compounds from psilocybin fungus | |
EP4161549A1 (en) | Process for obtaining a purified psychoactive alkaloid solution | |
CA3169140A1 (en) | Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids |